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ABSTRACT
Background Chronic heart failure, a common cause of morbidity and mortality, is
frequently associated with sleep-disordered breathing, which may be detrimental
through a variety of haemodynamic, autonomic and vascular mechanisms. Whilst
associated with increased morbidity and mortality, sleep-disordered breathing is often
unrecognised and yet presents a potential therapeutic target in patients with chronic
heart failure.
Objectives The aims of the thesis were, in patients with stable symptomatic
chronic heart failure treated with optimal contemporary heart failure therapy: first, to
determine prospectively the prevalence of sleep-disordered breathing; second, to
compare the clinical characteristics of those patients with sleep-disordered breathing
to those without sleep-disordered breathing; third, to assess the accuracy and clinical
utility of a limited sleep study system, compared with polysomnography, for
diagnosing sleep-disordered breathing; and finally, fourth, to establish whether
treatment of obstructive sleep apnoea with nocturnal continuous positive airway
pressure improves subjective and objective measures ofheart failure severity.
Methods Patients with stable symptomatic chronic heart failure were screened
for sleep-disordered breathing by home sleep study. Daytime sleepiness was assessed
by Epworth Sleepiness Scale and heart failure severity by symptom class, left
ventricular ejection fraction and serum N-terminal pro-brain natriuretic peptide
concentrations. In a subset ofpatients, synchronous in-laboratory limited sleep studies
and polysomonography, and home limited sleep studies, were performed
prospectively. Patients with obstructive sleep apnoea and stable symptomatic chronic
heart failure were randomised to nocturnal auto-titrating continuous positive airway
pressure or sham for six weeks each in crossover design. Study co-primary endpoints
were changes in peak VO2 and six minute walk distance and secondary endpoints
changes in left ventricular ejection fraction, VE/VCO2 slope, neurohormonal markers
and quality of life.
Results In the era ofmodern therapy, sleep-disordered breathing is common in
patients with stable symptomatic chronic heart failure, predominantly obstructive in
aetiology, without clear relationship to heart failure severity and is difficult to
diagnose because ofmajor overlap in symptomatology. Limited sleep studies compare
well diagnostically to polysomnography when tested under identical patient and
environmental conditions but less so when tested in the home setting. Auto-titrating
continuous positive airway pressure improves daytime sleepiness in patients with
obstructive sleep apnoea and chronic heart failure but not other subjective or objective
measures of heart failure severity.
Conclusions Sleep-disordered breathing is difficult to detect clinically in patients
with chronic heart failure, and as such, the diagnosis is reliant on accurate sleep
studies. However, the clinical utility of limited sleep studies in detection and
diagnosis of sleep-disordered breathing is restricted by a number of technical and
situational factors which are exacerbated in patients with chronic heart failure. The
potential therapeutic benefits of continuous positive airway pressure in patients with
obstructive sleep apnoea and chronic heart failure are achieved by alleviation of
obstructive sleep apnoea rather than by improvement in cardiac function; however,
efficacy of continuous positive airway pressure therapy may in part be limited by poor
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SLEEP-DISORDERED BREATHING AND CHRONIC HEART
FAILURE
1
1.1 DEFINITIONS AND EPIDEMIOLOGY
1.1.1 Chronic Heart Failure
Chronic heart failure (CHF) is a complex clinical syndrome resulting from structural or
functional cardiac disorder which impairs the ability of the left ventricle to fill with or
eject blood. It is characterized by dyspnoea and fatigue, which may limit exercise
tolerance, and fluid retention, which may cause peripheral oedema and pulmonary
congestion^ 1) Potential underlying causes of CHF are therefore numerous, but
ischaemic heart disease is the most common in developed countries. Epidemiological
studies have identified hypertension, diabetes mellitus, obesity and smoking as risk
factors for the development ofCHF.(2)
CHF is a major cause of morbidity and mortality in developed countries and its
prevalence and incidence continue to rise.(3) In the United States it is estimated 5
million people are receiving treatment for CHF, there are 550 000 new cases each year
and CHF contributes to almost 287 000 deaths per year.(4) These observations have led
to suggestions that CHF is a 'disease of epidemic proportions', both in the United States
and in Europe.(5;6) Potential explanations for the increasing morbidity and mortality
associated with CHF (figure 1.1) include an ageing population and reducing acute
cardiovascular mortality. The resulting clinical and economic burden on healthcare
systems and society, through direct medical costs, disability and loss of employment, is
great; indeed the estimated direct and indirect cost of CHF in the United States for 2006
was $29.6 billion. (4)
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Figure 1.1
Hospital discharges for heart failure by sex (United States: 1970-2003). Note: Hospital
discharges include people discharged alive and dead. Source: National Hospital
















Current management guidelines, after identification and treatment of treatable causes,
recommend dietary and lifestyle advice, optimisation of drug and device therapy and, in
appropriate cases, consideration of advanced CHF therapies such as left ventricular
assist devices and heart transplantation, all in the context of a program of regular
monitoring by healthcare professionals.(l;7) There have been important recent advances
in drug and device therapy for patients with CHF with ACE inhibition, angiotensin
receptor blockade, beta-blockade, spironolactone, cardiac resynchronisation and
implantable defibrillator therapy all having proven morbidity and mortality benefits.(8-
17) Series of clinical trials have demonstrated improvements in survival of patients with
CHF with changes in baseline therapy. Whereas patients with symptomatic CHF treated
with digoxin and diuretic therapy in the Veterans Administration Cooperative study had
a 2 year mortality rate of 34%, the recent COMPANION trial reported a 1 year
mortality of <10% in similar patients treated with ACE inhibition, beta-blockade and
aldosterone antagonism.(8;18) However, despite these advances, patients with CHF still
follow a typical course of declining quality of life, frequent hospital admissions, and
ultimately premature death from progressive pump failure or cardiac arrhythmias. The
identification ofpotential exacerbating factors and possible therapeutic targets therefore
remains extremely important.
1.1.2 Sleep-Disordered Breathing
Non-rapid eye movement (NREM) sleep, accounting typically for 85% of total sleep, is
a period of cardiovascular relaxation characterized by decreased heart rate, cardiac
output, systemic vascular resistance, metabolic rate and sympathetic nervous system
activity.( 19-21) In contrast rapid eye movement (REM) sleep, approximately 15% of
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total sleep, is associated with intermittent bursts of sympathetic nervous system activity;
because NREM sleep is dominant, average sleeping blood pressure and heart rate
remain lower than during waking hours.(20) Sleep is generally reduced and of poorer
quality in patients with CHF.(22-24) The presence of sleep-disordered breathing (SDB)
may further disrupt the normal relaxant effects of sleep on the cardiovascular system
with detrimental consequences.
Sleep-disordered breathing is characterised by recurrent apnoeas and hypopnoeas
causing disruption of normal ventilation and sleep architecture. Cessation of breathing
may be due to upper airway obstruction (obstructive; see figure 1.2), loss of ventilatory
effort (central; see figure 1.3) or a combination of both (mixed). Upper airway
obstruction leads to increasing effort to produce airflow resulting in increasing thoraco¬
abdominal wall movements which are out of phase. In contrast, central sleep apnea is
characterized by absence of thoraco-abdominal movement. Cheyne-Stokes respiration
(CSR) is a particular form of central sleep apnea which was reported by John Cheyne
and William Stokes in a patient with heart failure in 1818, and previously observed by
another physician, John Hunter.(25-28) CSR describes a type of periodic breathing,
where there are cyclical fluctuations in the amplitude of tidal volume, typically in a
gradual crescendo-decrescendo pattern interspersed with periods of central apnea (see
figure 1.3).(29) SDB reflects a spectrum and may be asymptomatic or lead to significant
morbidity and mortality. Severity can be defined clinically e.g. based on sleepiness or
on pathophysiological measurements e.g. apnoea-hypopnoea index (AHI) or respiratory
disturbance index or by a combination of the two. The term obstructive sleep apnea-
hypoponea syndrome (OSAHS) is used where recurrent partial or complete upper
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airway obstruction during sleep (OSA) occurs with a specified frequency and is
associated with symptoms.(30)
The exact prevalence of SDB is difficult to ascertain due to variations in definitions and
diagnostic criteria chosen and also because risk factors for SDB are increasing. The
prevalence of SDB in healthy middle-aged adults is estimated to be 4-9%.(31-34) Risk
for SDB increases with both age and body mass index.(32;35-37) Racial and genetic
influences are also important with increased risk of SDB observed in those with a
family history of SDB and also in those with African- American, Asian and Hispanic
origin.(38-40) The prevalence of SDB is lower in women than in men, an observation
which may be explained in part by hormonal factors.(33;41) Risk in women increases
with obesity and also with post-menopausal status.(33;34;42) SDB is more prevalent in
smokers than non-smokers and may be exacerbated by factors such as alcohol intake
and sedative use.(33;43;44) It is also associated with other medical conditions such as
CHF, stroke, hypothyroidism, nasal obstruction and rhinitis, tonsillar and adenoidal
enlargement and craniofacial abnormalities.(33;45-49) The Cleveland Family Study has
recently reported the incidence of developing SDB, defined by AHI greater than 5
events per hour and by 15 events per hour, to be 7% and 2% per year respectively.(50)
The prevalence of SDB observed in patients with CHF due to left ventricular systolic
dysfunction is much higher than in the general population. Early studies reported a
prevalence of SDB (AHI > 15 events per hour) of 43 - 82% in patients with stable
CHF.(23;29;49;51-54) All but one of these studies reported a predominance of CSA,
observed in 29 - 62% of patients with CHF, compared to OSA which was seen in 5 -
6
32%. However, these studies predate recent advances in CHF therapy which have
impacted on morbidity and mortality.(16;17) More recent work has produced
conflicting results suggesting a prevalence of SDB between 24 and 71% in this patient
population with no consensus on the predominant type of SDB.(55-60) Previously
identified risk factors for CSA include age greater than 60 years, male gender, atrial
fibrillation and hypocapnia; others report an association between CSA and indices of
increased severity of CHF.(23;55-58) Sin et al found obesity to be a risk factor for OSA
in men with CHF.(23) The reasons for the increased prevalence ofOSA in patients with
CHF compared to the general population are not well defined, but may in part be due to
common risk factors such as obesity and metabolic syndrome.
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Figure 1.2(61)
Sleep hypnogram and oximetry tracing in a patient with severe OSA (AHI 84/hr) and
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Example ofCSA - CSR: note the crescendo/decrescendo pattern of respiration, absence





1.2.1 Control of ventilation
The physiological mechanisms controlling ventilation can be loosely divided into
metabolic, behavioural and wakefulness systems.(63) Metabolic control includes
interaction between chemoreceptors, intrapulmonary vagally-mediated receptors and
brainstem mechanisms and matches ventilation to current metabolic and homeostatic
requirements. Behavioural control involves neural input from the forebrain and the
wakefulness system describes the increased ventilation observed whilst awake. During
sleep, however, ventilation is almost solely controlled by the metabolic system. Arterial
pCCh plays a key role in maintaining stable and rhythmic ventilation during sleep.(64)
There is a linear relationship between increasing pCC>2 and ventilation. This ensures that
only a small rise in pCC>2 is required to stimulate increased ventilation. In contrast the
relationship between arterial pC>2 and ventilation is a hyperbolic one and as such
relatively large changes in pC>2 have minimal effect on ventilation. The body's own
stores of CO2 ensure that large changes in ventilation are needed to alter the pCC>2 and
as such this provides a damped and stable feedback system.
1.2.2 Obstructive sleep apnoea
Patency of the upper airway is maintained by a dynamic combination of activity of the
surrounding muscles and negative intra-luminal pressure. Abnormalities in upper airway
anatomy and neuromuscular control by the higher nervous system may lead to a
narrowed and more collapsible pharyngeal airway. Sleep is associated with reduction in
pharyngeal muscle tone further predisposing to upper airway obstruction.(65) Obesity
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decreases upper airway size as a result of increased deposition of adipose tissue in the
surrounding structures and also greater airway collapsibility due to increased muscle
mass.(66-70) Patients with CHF may develop increased pharyngeal oedema associated
with supine posture during sleep which may further contribute to narrowing of the upper
airway.(71;72)
Repeated inspiration against the occluded upper airway generates exaggerated negative
intra-thoracic pressure, increased systolic trans-mural pressure, increased left ventricular
afterload and reduced stroke volume and cardiac output. The exaggerated negative intra¬
thoracic pressure also causes increased venous return and right ventricular overload
further impairing left ventricular filling.(73;74) In addition, there is repetitive hypoxia,
hypercapnia, arousals from sleep, surges in sympathetic activity and loss of vagal heart
rate regulation (figure 1.4). Consequently, OSA is associated with systemic
hypertension, vascular endothelial dysfunction, increased sympathetic nervous system
activity, increased concentrations of inflammatory mediators, increased insulin
resistance and cardiac arrhythmias, factors which may all contribute to the progression
ofCHF.(75-82)
1.2.3 Central sleep apnoea
Instability of ventilatory control is implicated in the development of CSA and CSR.
Patients with CHF have increased circulation time, increased ventilatory responsiveness
to pCCF and reduced functional residual capacity, factors which are all implicated in the
development of periodic breathing.(83-85) Increased circulation time leads to delay in
transfer of information from pulmonary capillaries to the chemoreceptors regarding
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changes in CO2 and O2 arterial tension. Lung-to-chemoreceptor circulation time and
CSR cycle length have been shown to correlate in patients with CHF.(86) In patients
with increased chemoreceptor sensitivity to CO2, small increase stimulates
hyperventilation. Consequentially, pCC>2 falls below the apnoea threshold and central
apnoea ensues until pCC>2 rises again to the level required to stimulate hyperventilation
thus maintaining the cycle of periodic breathing.(87-92) Hypoxaemia in CCF is
generally mild and therefore not of the severity to cause hyperventilation. Reduced
functional capacity introduces 'underdamping' within the control system.(83;84)
Changes in pCC>2 and pC>2 are augmented for any given change in ventilation.
Functional capacity in patients with CHF may be reduced by cardiomegaly, pleural
effusions and decreased respiratory system compliance.
CSA shares many of the pathophysiological effects of OSA with recurrent nocturnal
hypoxia, excessive arousals, shift to light sleep stages and activation of the sympathetic
nervous system but differs in that there is no generation of exaggerated negative
intrathoracic pressure (figure 1.5).(93) However, it is now recognised that patients with








Pathophysiological scheme ofCSA in CHF
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1.3 CLINICAL RELEVANCE OF SLEEP-DISORDERED BREATHING IN
CHRONIC HEART FAILURE
SDB contributes to both morbidity and mortality in patients with CHF. Patients with
SDB may complain of fatigue, daytime sleepiness, morning headache, poor
concentration, insomnia, nocturnal angina and nocturia. Snoring and abnormal breathing
patterns may be witnessed by bed partners. However, it can be seen that there is
considerable overlap between the symptoms of SDB and those of CHF, and it is likely
that this contributes both to under-reporting and under-diagnosis of SDB in these
patients.
1.3.1 Obstructive Sleep Apnoea
There is increasing evidence that OSA is an independent risk factor for fatal and non¬
fatal cardiovascular events.(97-102) Marin et al reported 2.9 and 3.2 fold higher rate of
fatal and non-fatal cardiovascular events respectively in those with severe untreated
OSA compared to healthy subjects, after controlling for confounding variables.(97) The
cross-sectional Sleep Heart Health Study showed that OSA increased the odds of having
CHF by 2.2 fold compared to those without OSA.(98) Furthermore, specifically in
patients with CHF, untreated OSA is associated with an increased risk of death
independent of other confounding factors (see figures 1.5 and 1.6).(103)
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Figure 1.6(97)
Cumulative percentage of individuals with new fatal (A) and non-fatal (B)





Controls 764 762 259 258
Sisorets 377 372 361 232
Mild 05AH 403 401 392 264
Severe 0S4H 735 279 221 167
05AH with CPAP 372 364 361 229
14
Figure 1.7(103)
Multivariable Cox proportional hazards plots showing worse survival of heart failure
patients with untreated obstructive sleep apnea (OSA) than in those with mild to no
sleep apnea (M-NSA) (hazard ratio = 2.81, p = 0.029) after adjusting for significant




1.3.2 Central Sleep Apnoea
Several studies have shown that CSA is a risk factor for increased mortality in patients
with CHF.(51;104-108) However, these studies predate recent advances in drug and
device therapy for CHF. Indeed a fall in the combined rate of heart transplantation and
mortality in patients with CHF and CSA was observed during the course of the
Canadian Continuous Positive Airway Pressure for Treatment ofCentral Sleep Apnea in
Heart Failure (CANPAP) trial and was associated with increasing use of beta-blockers,
which inhibit excessive sympathetic nervous system activity.(109) Subsequently,
patients with CHF receiving interventions of proven benefit in CHF such as beta-
blocker and cardiac resynchronisation therapy have been shown to have lower
prevalence and severity ofCSA.(110; 111) Furthermore, CSA is associated with markers
of increased severity of CHF and its presence may simply be an indicator of elevated
left ventricular filling pressures and decompensated CHF which confer poorer
prognosis.(55-58)
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1.4 DIAGNOSIS OF SLEEP DISORDERED BREATHING IN PATIENTS
WITH CHRONIC HEART FAILURE
1.4.1 Diagnostic Criteria
The diagnosis and classification of SDB are based on a combination of symptoms and
signs and the findings of nocturnal sleep studies. Symptoms may be assessed by direct
questioning and completion of sleep-specific questionnaires by the patient and their
partner. Symptoms include excessive daytime sleepiness not explained by other factors,
nocturnal choking or gasping, recurrent nocturnal arousals or awakenings, unrefreshing
sleep and impaired concentration. The AHI, determined by PSG, is used primarily to
quantify SDB and respiratory events are classified as obstructive, central or mixed in
aetiology. Five, or more, respiratory events per hour of sleep are regarded to be
significant.(30) There is currently no clear consensus in some aspects of respiratory
event scoring, most notably regarding the definition of a hypopnoea.(l 12)
1.4.2 Sleep Studies
The American Academy of Sleep Medicine Task Force recognises four levels of sleep
study.(30) A level I study involves complete attended overnight PSG performed in the
sleep laboratory. This enables determination of sleep and wake states, sleep stages and
disturbance, AHI and detection of sleep pathology unrelated to SDB. A level II study
also consists of complete PSG but differs in that it is unattended and performed in the
home setting. Level III studies involve the use of portable limited systems and can also
be used in the home. These record nasal or oral airflow, respiratory movement,
oximetry, pulse rate and sleep position but provide no information regarding wake and
17
sleep states or sleep stages and disturbance. Level IV studies record only pulse rate and
oximetry, thus providing very limited information.
A level I study is considered generally to be the gold standard in the diagnosis and
classification of SDB. However, PSG is relatively expensive, not widely available and
demand exceeds supply, at a time when only a minority of patients with CHF is
investigated for SDB.(113) Level III studies have been shown to be useful and cost-
effective in the diagnosis ofOSAHS. However they have not been validated in patients
with CHF and therefore no guidance exists for their use in this specific patient
population^ 114-119) Level IV studies are not recommended for the diagnosis and
classification of SDB but have a role as a screening tool for OSAHS in the adult
population.
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1.5 TREATMENT OF SLEEP-DISORDERED BREATHING IN PATIENTS
WITH CHRONIC HEART FAILURE
1.5.1 Continuous Positive Airway Pressure
Nocturnal CPAP is a well established treatment for OSAHS which improves daytime
sleepiness, quality of life, cognitive function, impotence, road traffic accidents,
hypertension and other cardiovascular disease, and mortality.(76;97;120-130) CPAP is
applied via a nasal or oronasal mask, typically with pressure range 5-15 cm H2O. It
splints open the entire airway preventing upper airway collapse and increases functional
residual capacity. Recently, auto-titrating CPAP has become available.(131;132) This
device automatically adjusts pressure according to upper airway obstruction, avoiding
many of the disadvantages of titration and treatment with conventional CPAP. It is as
effective as fixed pressure CPAP in reducing daytime sleepiness and AHI, increases
nightly use and provides better quality sleep and less discomfort.(133;134)
Potential side-effects of CPAP therapy include mask discomfort, claustrophobia, nasal
congestion, rhinorrhoea, epistaxis and conjunctivitis. Most of these can be minimised by
good mask fitting, patient education, air humidification and possibly nasal
decongestants.(135; 136) These factors may contribute to problems with compliance,
especially in the longer term; indeed, only 50-60% patients may comply with
therapy.(137-139) Previous work in patients with OSAHS has shown that there is a
need to derive symptomatic benefit from CPAP in order to accept the associated
discomfort and inconvenience.(140) Auto-titrating devices may produce better
compliance rates due to lower pressure use.
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1.5.1.1 Obstructive Sleep Apnoea
Nocturnal CPAP alleviates acute OSA and reduces nocturnal heart rate, blood pressure
and left ventricular afterload.(74;141) Medium term use in patients with OSA and CHF
reduces AHI and improves quality of life and cardiovascular function.(142-144) These
studies employed parallel group comparisons with small numbers of patients (n=12-19
per group) and no placebo control.(142;144) Absolute increases in left ventricular
ejection fraction (LVEF) of 5-12% were reported with 1-3 month use of nocturnal
CPAP. Mean CPAP usage varied between 5.6 and 6.2 hours per night. Reductions in
daytime blood pressure, sympathetic nervous system activation and ventricular ectopy
have also been observed.(142;144-146) The long term impact of CPAP on
cardiovascular outcomes in patients with OSA and CHF is unknown.
1.5.1.2 Central Sleep Apnoea
In patients with CSA and CHF, CPAP increases intra-thoracic pressure, reduces left
ventricular transmural pressure and afterload, and reduces left ventricular preload, all of
which contribute to a more favourable haemodynamic profile.(53;147) When applied
with sufficient pressure for a period of 2-12 weeks, CPAP reduces central
AHI.(109;147-150) CPAP is also associated with improvements in symptoms,
inspiratory muscle strength, neurohormonal concentrations, sympathetic nervous system
activation, functional mitral regurgitation and LVEF.(106;147;149-153) Sin et al
reported that patients with CSA and CHF who were compliant with CPAP therapy had a
relative risk reduction of 81% (95% CI 26-95%, p=0.017) in a combined endpoint of
death and cardiac transplantation during a median follow-up period of 2.2 years.(106)
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The multi-centre CANPAP trial aimed to investigate the effects of long term CPAP on
cardiovascular outcomes in patients with CSA and CHF. It is the largest trial to date of
CPAP in patients with CHF involving randomisation of 258 patients.(109) However, the
trial was terminated early due to a divergence in survival curves which favoured the
control group, lower than expected enrollment and a falling primary event rate,
associated with a changing pattern of drug therapy.
The CANPAP trial did show, that CPAP use was associated with sustained
improvements (over a minimum of 2 years) in CSA, nocturnal oxygenation, exercise
capacity, LVEF and plasma norepinephrine concentrations, although with lesser
magnitude than previously observed. However, the finding of early adverse outcomes in
the group treated with CPAP is of particular concern, something not identified
previously in smaller studies. CPAP-induced increases in intrathoracic pressure usually
augment cardiac output acutely in patients with CHF with elevated left ventricular
pressures but may reduce it in those with low filling pressures.(154) This is one
potential haemodynamic mechanism whereby CPAP may have deleterious effects in
some patients with CHF and CSA. This possibility of early harm does not support the
use ofCPAP in CHF patients with CSA outside the setting ofwell-designed randomised
controlled trials.
Subsequent post hoc analysis of the CANPAP data was performed to test the hypothesis
that suppression ofCSA to AHI less than 15 events per hour would improve both LVEF
and transplant-free survival.(155) This analysis showed that, compared with control
subjects, increases in LVEF and transplant-free survival were greater in the CSA-
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suppressed group. However, concerns regarding this interpretation include differences
in the baseline characteristics between the untreated controls and both CPAP-treated
groups, as well as the inherent problems withpost hoc analysis.(156)
1.5.2 Bi-level and adaptive servo-ventilation
Other modes ofpositive airway pressure, namely bi-level pressure support and adaptive
servo-ventilation (ASV), have been evaluated in patients with CHF. Bi-level non¬
invasive ventilation enables differing inspiratory and expiratory pressure support. ASV
provides 5cm and 8cm H2O expiratory and end-inspiratory pressure respectively during
normal breathing but when central apnea is detected it increases end-inspiratory
pressure up to a maximum of 15 cm H?0 to maintain minute ventilation at 90% of the
longer-term average ventilation.
Teschler et al compared oxygen therapy, CPAP, bi-level pressure support and ASV on
consecutive nights in patients with CHF and found significant reductions in CSA with
all therapies; however improvements in sleep structure were only observed with
ASV.(157) Kohnlein et al compared bi-level ventilation to CPAP over a 2 week period
in patients with CHF and found similar improvements in daytime sleepiness, sleep
quality and CSA but did not assess cardiac function.(148) Pepperell et al conducted a
randomized controlled trial of therapeutic and sub-therapeutic ASV in patients with
CHF and CSA and reported improvements in daytime sleepiness, urinary metanephrine
and plasma BNP concentrations, but not in LVEF.(158) These findings contrast with the
results from another study comparing ASV and CPAP which showed improvements in
LVEF in the group treated with ASV.(159)
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1.5.3 Other treatment modalities
Modification of lifestyle factors may be beneficial in reducing SDB.(160) Patients
should be advised regarding weight reduction, if obese, and also regarding smoking and
alcohol cessation. Sedative drugs should be avoided if possible. Optimisation of CHF
therapy may itself reduce CSA.(53;111;161;162) Nocturnal supplemental oxygen
therapy has been shown to reduce central AHI and possibly nocturnal sympathetic
activity but current data do not suggest improvements in either symptoms or cardiac
function.(149;163-166) Furthermore, hyperoxia may have adverse physiological
effects.(167; 168) Respiratory stimulants, such as theophylline and acetazolamide, have




SDB in patients with CHF often passes unrecognized and yet is associated with
increased morbidity and mortality, and presents a potential therapeutic target.(51; 107)
Early studies have reported that SDB is highly prevalent in patients with CHF, with a
predominance of CSA rather than OSA.(23;49;52) However, these data predate recent
important advances in drug and device therapy, which have improved morbidity and
mortality, and are now widely adopted in guidelines for the optimal management of
patients with CHF.(1;7;15-17)
The symptoms of SDB and CHF overlap and, as such, the diagnosis of SDB is reliant
on accurate sleep study measurements. Portable limited sleep study systems, which do
not record an electroencephalogram and are applied by patients at home, are a more
accessible alternative to full polysomnography (PSG).(l 13; 114) They have been well-
validated against PSG in the investigation ofOSAHS in the general population but there
are few data specifically in patients with CHF.(30;114;119; 172; 173)
There have been only two previous randomized controlled trials to assess CPAP in
patients with CHF and OSA.(142;144) These trials reported that CPAP therapy
improved symptoms, LVEF and systolic blood pressure. However, these studies had
important limitations including the single blind design, the small numbers of patients
(n=12-19 per intervention group) completing study protocols and findings which were
not entirely consistent. The effect ofCPAP on cardiovascular outcomes in patients with
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CHF and OSA therefore is an extremely important clinical question which remains
unanswered.
The following hypotheses will be addressed:
1. The prevalence of SDB in patients with CHF treated with optimal medical
therapy according to contemporary guidelines is lower than previously reported
and is due to a reduction in CSA.
2. There is good agreement in diagnostic outcome between home limited sleep
studies and in-laboratory polysomnography in the identification of SDB in
patients with CHF.
3. Treatment of OSA in patients with symptomatic stable CHF by nocturnal auto-
titrating CPAP:
i. is a tolerable method of adjunctive ventilatory support
ii. improves exercise capacity, peak oxygen uptake and LVEF
iii. improves New York Heart Association class and quality of life measures
iv. reduces plasma catecholamine, N-terminal pro-brain natriuretic peptide
and N-terminal pro-atrial natriuretic peptide concentrations
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1.7 AIMS
The aims of the thesis were:
In patients with stable symptomatic CHF (Chapter 3):
• to determine prospectively the prevalence of SDB in the setting of optimal
medical therapy according to contemporary guidelines.
• to investigate the clinical characteristics of patients with SDB compared to those
without SDB.
In patients with stable symptomatic CHF (Chapter 4):
• to assess the accuracy and clinical utility of a limited sleep study system
performed at home, compared with in-laboratory polysomnography, for
diagnosing SDB.
In patients with stable symptomatic CHF and OSA (Chapter 5):
• to determine whether, by randomized controlled crossover trial, treatment of
OSA by nocturnal auto-titrating CPAP would improve subjective and objective
measures ofCHF severity.







All studies were undertaken in accordance with the Declaration of Helsinki of the
World Medical Association and with the approval of the Lothian and North Glasgow
NHS Trust Research Ethics Committees.
All patients participated in these research studies voluntarily. They were all deemed
competent to consent and able to consider fully and rationally the implications of taking
part. They were provided with adequate information in the form of a detailed patient
information sheet and also given the opportunity to discuss further both with trial
investigators and also an independent advisor. The written informed consent of each
patient was obtained before entry into the study, after a period ofmore than 24 hours of
consideration. Participants were able to withdraw consent at any time without hindrance
or detriment to their future treatment. Measures were taken to safeguard patient
confidentiality. The use of identifiable information was minimised and data anonymised
wherever possible. Research records, both paper and electronic, and anonymously
labeled specimens were stored in a secure manner only accessible to authorised
personnel. Confidential information was used only for the purpose it was obtained and
no individual was identifiable from published results.
2.1.2 Subject recruitment
Patients were recruited from general cardiology clinics at two university hospitals in
Edinburgh and from a specialist heart failure clinic in Glasgow. Consecutive patients
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aged between 18 and 80 years with symptomatic (NYHA class II-IV) but stable CHF
for at least one month on optimal medical therapy and objective evidence of left
ventricular systolic dysfunction (echocardiographic LVEF < 45%) were enrolled
prospectively. Furthermore, to be eligible for inclusion in the randomised placebo-
controlled trial of auto-titrating CPAP in patients with CHF and OSA, they had to also
have an AHI >15 (predominantly obstructive) on PSG. Exclusion criteria were acute
coronary syndrome within the preceding three months, implantation of a pacemaker or
defibrillator within the preceding six months, primary valvular heart disease, sustained
ventricular arrhythmias (but not atrial fibrillation) and stroke with residual neurological
deficit. Patients who had undergone recent implantation of a cardiac pacemaker or
defibrillator were excluded because of concerns that this might independently affect
trial endpoints.
Nine patients participated in both the evaluation of a portable limited sleep study system
in the diagnosis of SDB (Chapter 3) and the randomised controlled trial of CPAP in
OSA (Chapter 5). All of the patients enrolled in these two studies participated in the
prospective evaluation of the contemporary prevalence and type of SDB in patients with
CHF (Chapter 4).
2.1.3 Considerations of study design
The intervention trial was designed in a randomised double-blind placebo-controlled
crossover format to enable patients to act as their own control, thus reducing between-




Randomisation to treatment order, where indicated, was performed following baseline
assessment using sealed envelopes and a balanced block design.
2.1.5 Blinding
Investigators blinded to intervention modality undertook all measurements and analyses.
Specifically, they were not involved in randomisation, device education or follow-up,
and study participants were requested not to discuss their device therapy with them.
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2.2 SLEEP STUDIES
2.2.1 Limited sleep studies
Limited sleep studies were performed using a commercially available system (Embletta;
Flaga, Iceland) measuring: 1) nasal pressure using a nasal cannula/pressure transducer
system (recording the square root of pressure as an index of flow), 2) thoraco-abdominal
movement from two piezoelectric belts, 3) finger pulse oximetry and 4) body position.
Patients were educated in the application of the Embletta device prior to the study and
applied the device themselves at home. They were provided with written instructions
and a night-time telephone number to call in the event of difficulties. Patients required
sufficient agility to apply the thoraco-abdominal bands, nasal cannula and pulse
oximeter and connect a single connector to the recording device. No calibration was
required.
2.2.2 Polysomnography
Polysomnography was performed following our standard laboratory protocol with a
computerised recording system (Compumedics, Abbotsford, Australia) consisting of: 1)
sleep monitoring through electro-encephalogram, electro-oculogram, and submental
plus outer canthi electromyogram, 2) bilateral tibial electromyogram and body position
detector, 3) nasal pressure using a nasal cannula/pressure transducer system, 4) thoraco¬
abdominal movement from two inductance plethysmographic belts, 5) finger pulse
oximetry, 6) snoring detection by digital microphone and 7) three-lead
electrocardiogram./172)
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2.2.3 Oxford SLEep Resistance test
During the Oxford SLEep Resistance (OSLER) test, the subject is placed semi-
recumbent in a dark and quiet environment and requested to remain awake for a
maximum testing time of 40 minutes.(174-176) The presence of sleep is assessed
behaviourally. Subjects are asked to touch a non-recoil button (Stowood Scientific
Instruments, Oxford, U.K.) each time a light flashes on a socket placed in front at eye
level at a distance of 2 metres. The light flashes regularly for 1 second every 3 seconds.
The LED and hand response device are relayed to a computer in an adjacent room. The
test is terminated after seven consecutive flashes without response, assuming that the
subject has been asleep. The OSLER test has been successfully validated against the
maintenance of wakefulness test in the evaluation of objective daytime
sleepiness.(175; 176) The initial description of the test describes repetition of each
session four times at two hourly intervals with the overall result calculated as the mean
of all four sessions. However, we elected to perform an abbreviated OSLER test
repeating each session twice (commencing at 9 and 11 am) after a normal sleep night
and abstinence from caffeine or other wakefulness stimulants. Reducing the number of
testing sessions has previously been shown not to significantly affect the overall
result.(176)
2.2.4 Data analysis
All sleep studies were scored according to standard criteria by the same experienced
sleep technician^ 177) PSG enables two states of sleep, NREM and REM sleep, and four
stages within NREM sleep to be determined. Stage 1 is light sleep occurring at sleep
onset and transitions during the night. Stage 2 is defined by sleep spindles and K
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complexes in the EEG. Stages 3 (20-50%) and 4 (>50%) are characterized by high-
voltage slow waves in EEG and are known as slow-wave sleep. REM sleep is
distinguished by relatively low voltage mixed frequency EEG, bursts of rapid eye
movements in the EOG and suppression ofEMG activity.
A summary of definitions of respiratory events and indices is presented in Table 2.2.
Currently several definitions are in use and there is a lack of consensus. In accordance
with our current research and clinical practice, apnoeas were defined as a complete
cessation in airflow lasting >10 s, and hypopnoeas as a reduction in airflow or thoraco¬
abdominal movement by >50% for >10 s. Apnoeas were classified as 1) obstructive if
thoracoabdominal movement was present during the apnoea; 2) central if thoraco¬
abdominal movement was absent; and 3) mixed if thoraco-abdominal movements were
both present and absent during the period of airflow cessation. (30) We used the
American Academy of Sleep Medicine definition of significant respiratory events which
does not require oxygen desaturation when flow is measured by nasal pressure rather
than thermal signal.(30) Flow was recorded by nasal pressure in addition to thoraco¬
abdominal movement and these signals were used to identify hypopnoeas. Hypopnoeas
cannot be differentiated with certainty between central or obstructive from surface
techniques and therefore events per hour are reported rather than central and obstructive
events separately.
The Embletta device does not record sleep and therefore only an apnoea/hypopnoea
measure per hour in bed, rather than an AHI, can be calculated. For Embletta studies
performed at home, analysis was started once respiration settled to a stable rhythmic
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pattern and stopped either according to the time of awakening as provided by the patient
or based on tracing quality and breathing pattern. The start and end of the laboratory
Embletta analysis were set according to the start and end time of the synchronous PSG.
For the synchronous PSG studies, both AHI and apnoea/hypopnoea measure per hour in
bed were calculated to enable direct comparison of techniques.
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Table 2.1
Definitions ofRespiratory Events and Indices
Respiratory
event Definition
Apnoea Complete cessation of airflow >10 seconds.
Hypopnoea Reduction in airflow or thoraco-abdominal movement by >50% for
>10 seconds.
Several definitions are in use (including need for association with
EEG arousal or oxygen desaturation) & there is currently a lack of
consensus.
RERA Sequence of breaths with increasing respiratory effort leading to an
arousal as shown by increasingly negative oesophageal pressure for
>10 seconds preceding an arousal with resumption ofmore normal
pressures.




Obstructive Thoraco-abdominal movement present during event
Central Thoraco-abdominal movement absent during event
Mixed Thoraco-abdominal movement both present and absent during event
Indices of SDB
AHI Number of apnoeas & hypopnoeas per hour of total sleep time.
Apnea index Number of apnoeas per hour of total sleep time.
Hypopnoea
index
Number ofhypopnoeas per hour of total sleep time.
A+H Number of apnoeas & hypopnoeas per hour in bed.









Number of oxygen desaturations >3-4% per hour of total sleep time.
Adapted from Kushida et al, 2005.(178)
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2.3 NON-INVASIVE VENTILATION
2.3.1 Continuous positive airway pressure
Auto-titrating CPAP automatically adjusts pressure according to upper airway
obstruction. It is as effective as fixed pressure CPAP in reducing daytime sleepiness
and AHI and avoids many of the disadvantages of titration and treatment with
conventional CPAP.(133;134) Patients underwent an initial daytime education session
and were then supervised for their first night on each device in the Sleep Centre. They
were asked to use the machine for a minimum of six hours per night at home and
provided with a contact telephone number in case of any problems. In addition, all
patients were contacted by telephone by the Sleep Centre Research Nurse within 2
weeks of taking each device home. Compliance with therapy was assessed by
interrogation of the CPAP unit to provide nightly usage data.
2.3.2 Sham continuous positive airway pressure
Sham CPAP was chosen as the placebo in the interventional study. It was felt important
to control for placebo effect as this is a potential source of error. Previous studies with
CPAP in OSA have shown placebo effects with both tablets and sham CPAP.(127;140)
Failure to control for placebo effect therefore could overestimate differences in
endpoints between treatment and non-treatment limbs of the study. There is no perfect
placebo for CPAP since the placebo should ideally be indistinguishable from the active
treatment for both the investigator and the patient.(179) Sham ventilation is not
indistinguishable from assisted ventilation for the patient and this may lead to un¬
winding, non-compliance and increased drop-out rates. However, unlike a placebo
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tablet, it does control for the discomfort and possible sleep disruption of wearing a
facial mask overnight and observer blinding is easier to maintain. In addition, a placebo
tablet may not be perceived by the patient as a comparable therapy to CPAP thus adding
a further source ofbias.
Only one of the published trials in chronic heart failure and CPAP has used a placebo
control; sham CPAP was generated by setting delivered airway pressure to a minimum
and using a nasal mask with a hole drilled in the connector to reduce mask pressure to
less than 1.5 cm H2O.(180) Whilst only a small study involving 8 patients, the placebo
pressure was generally preferred. This strategy is well described in the literature for
studies of CPAP in OSA.(125;181-183) A comparison of CPAP versus sham CPAP in
OSA encouragingly showed very similar usage rates and no difference in respiratory or
neurological variables.(183) Study patients were informed that the two types of
breathing device were being compared, that they would receive both in a random order
and that it was unclear which was more effective.
The sham device was created by setting delivered airway pressure to a minimum,
inserting a flow-restricting connector at the machine outlet, and creating an extra hole in
the collar of the main tubing at the end of the mask. The device created a CPAP
pressure of~1 cm H20.
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2.4 ASSESSMENT OF SEVERITY OF CHRONIC HEART FAILURE
The parameters chosen to assess severity of CHF all provide important prognostic
information, whilst noting that LVEF correlates poorly with symptoms and functional
limitation.(184-187) Major treatment advances in the management of CHF, such as the
introduction of ACE inhibitors, beta-blockers, and, more recently, cardiac
resynchronization therapy, have been shown to improve these parameters and
subsequently, in large randomized controlled trials, to reduce hospitalisation rates and
mortality. (9; 13; 15; 16)
Study protocols were designed to enable assessments to be performed in the same
sequence and under the same testing conditions i.e. timing, preparation and
environment, enabling consistency of testing both between individual study participant
visits and also between different study participants.
2.4.1 Quality of life
Clinical assessment was performed at each study visit and NYHA class recorded.
Standardised and well-validated questionnaires (SF-36, Minnesota Living with Heart




Trans-thoracic Doppler echocardiography was performed by a single, experienced
research sonographer using an ATL HDI 5000 system (Philips Medical Systems
Limited, Stevenage, U.K). Left ventricular volumes and ejection fraction were
calculated according to modified Simpson's rule.
2.4.3 Exercise testing
At baseline evaluation, two 6 minute walk and two cardiopulmonary exercise tests were
performed on separate days to minimise any potential bias due to a training effect; the
second tests were taken as baseline data.
2.4.3.1 Six minute walk
A standardised test procedure was followed.(189) Patients were asked to walk around a
walking track, covering as much distance as possible during 6 minutes, and were
allowed to rest if required.
2.4.3.2 Cardiopulmonary exercise testing
2.4.3.2.1 Technique
Symptom-limited exercise tests were performed under physician supervision using an
electronically-braked cycle ergometer. The incremental exercise protocol was
individualised aiming for exercise duration between 8 and 12 minutes.(190) A 12-lead
electrocardiogram was monitored continuously during the test and cuff blood pressure
was recorded manually every two minutes. Patients were asked to exercise to
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exhaustion and all tests were conducted under physician supervision. Criteria for
terminating the test early included ischaemic ECG changes, ventricular arrhythmia,
hypotension (systolic BP < 90 mmHg), severe hypertension (systolic BP > 220 mmHg)
and patient request. Respiratory gas exchange measurements were obtained breath-by-
breath using a computerised metabolic cart (MSX, Ferraris Group Pic, Birmingham,
U.K). Gas and flow calibrations were performed before each test.
2.4.3.2.2 Data analysis
Breath-by-breath data were formatted using a rolling eight breath average. Peak VO2,
vco2 and ve were recorded as the highest such values within the last 30 seconds of the
test. Predicted peak VO2 values were calculated using the standard formulae described
by Wasserman et al.{ 191) The anaerobic threshold was determined non-invasively using
a dual method (V-slope and ventilatory equivalents) approach as the respiratory
exchange ratio approximated unity.(192) The Ve/VcCh slope was calculated as a linear
regression function, excluding the non-linear part of the relationship after the onset of
acidotic drive to ventilation.(190)
2.4.4 Neurohormonal markers
Venesection was performed after a period of 30 minutes rest in a semi-recumbent
position in a quiet room. Blood samples were collected in EDTA with additive trasylol
or 2% sodium metbisulphite and spun at 1000 g for 20 minutes at 4°C. The plasma was
then extracted and frozen in aliquots at -40 °C until analysis.
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2.4.4.1 N-terminal pro-brain and pro-atrial natriuretic peptides
NT-proBNP and NT-proANP were measured using a chemiluminescent immunoassay
(Roche Diagnostics Ltd, Lewes, U.K.) on an Elecsys 2010 analyser.
2.4.4.2 Plasma catecholamines
Plasma norepinephrine concentrations were determined by an electrochemical method
after separation by reverse phase high performance liquid chromatography. (193)
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2.5 STATISTICAL ANALYSIS
Data were collected and stored in accordance with the Data Protection Act. Statistical
analyses were performed using Statistical Package for Social Sciences version 10 (SPSS
inc., Chicago, U.S.A) and GraphPad Prism version 4 (GraphPad Software, San Diego,
U.S.A.) software. Continuous variables are expressed as mean values (±SD), or when
not normally distributed data as medians (interquartile range). Differences were
assessed by two-tailed, paired or unpaired, t-tests as appropriate. The Bland and Altman
method was used to assess agreement between two methods of clinical
measurement^ 194) Correlation between two measures was assessed by Pearson's, or
where not normally distributed, Spearman's method. NT-proBNP and NT-proANP data
were normalised by logarithmic transformation prior to analysis. The randomised
placebo-controlled trial of auto-titrating CPAP in patients with CHF and OSA had 80%
power, at 5% significance level, to detect absolute differences in primary end-points of
1.1 mL/min/kg in peak VO2 and 33m in 6-minute walk distance, assuming standard
deviation of expected changes of 1.9 mL/kg/min and 57 m respectively. Statistical
significance was taken at the 5% level.
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CHAPTER 3
DIAGNOSIS OF SLEEP-DISORDERED BREATHING IN
PATIENTS WITH CHRONIC HEART FAILURE:
EVALUATION OF A PORTABLE LIMITED SLEEP STUDY
SYSTEM
Smith LA, Chong WS, Vennelle M, Denvir MA, Newby DE, Douglas NJ. Diagnosis of
Sleep-Disordered Breathing in Patients with Chronic Heart Failure: Evaluation of a
Portable Limited Sleep Study System. J Sleep Res 2007;16:428-435
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3.1 SUMMARY
Sleep-disordered breathing is common in CHF, affects disease progression and presents
a potential therapeutic target. This study was designed to test the hypothesis that there
would be good agreement in diagnostic outcome between home limited sleep studies
and in-laboratory PSG in the identification of SDB in patients with CHF. We performed
synchronous in-laboratory Embletta and PSG, and home Embletta studies, prospectively
in 20 consecutive patients with stable symptomatic CHF (LVEF 33±12%) on optimal
medical therapy. Sleep efficiency was poor at 57±21%. Unlike synchronous in-
laboratory Embletta (kappa coefficient 0.63, p<0.01), home Embletta showed poor
agreement with PSG (kappa coefficient 0.27, p=0.06). Positive and negative predictive
values for home Embletta in detecting SDB were 83% and 57% respectively. In this
relatively small study, agreement in diagnostic outcome between home Embletta and
PSG, and negative predictive value for the home Embletta, were poor. We explore
possible explanations for this, both technical and situational, which should be taken into




Despite recent advances in pharmacological treatment, CHF is a common cause of
morbidity and mortality, and is an increasing clinical and economic burden on
healthcare systems.(3) CHF is frequently associated with SDB, including both OSA and
CSA. The reported prevalence varies according to the population studied and the
diagnostic threshold in AHI chosen, but may be as high as 61%.(23;49) OSAHS is
associated with systemic hypertension, vascular endothelial dysfunction, increased
sympathetic nervous activity and increased levels of inflammatory mediators.(78;80-82)
These important factors are all implicated in both the development and progression of
CHF. Randomised controlled trials in patients with OSA have shown that CPAP
improves cardiac function, sympathetic nervous system activity, quality of life and
reduces blood pressure.(142;144) CSA has similar deleterious effects and CSR, a form
of CSA, is an independent marker for increased mortality in CHF.(51;107) CPAP, and
more recently, adaptive servoventilation, have been shown to improve daytime
sleepiness, cardiac function and sympathetic activity.(147;158;163) However, in
contrast to previous work, the recently reported CANPAP trial did not demonstrate a
beneficial effect of CPAP on morbidity or mortality in patients with CHF and
CSA.(106;109)
The symptoms of CHF and SDB overlap, and whilst CHF patients with SDB have
objectively measured daytime sleepiness, few patients actually complain of
it.(22;49;195) As such, the diagnosis of SDB in CHF patients is reliant on accurate
sleep study measurements. Portable limited sleep study systems, which do not record an
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electroencephalogram and are applied by patients at home, are a cheaper and more
accessible alternative to full PSG.(113;114;119) They have been well-validated against
PSG in the investigation of OSAHS in the general population but there are few data
published specifically in patients with CHF.(22;30;114; 172). This study was designed
to test the hypothesis that there would be good agreement in diagnostic outcome
between home limited sleep studies and in-laboratory PSG in the identification of sleep-




The study cohort consisted of 20 consecutive consenting CHF patients aged between 18
and 80 years recruited from general cardiology out-patient clinics. Patients had a
diagnosis of symptomatic (NYHA class II-IV) but stable CHF for at least one month on
optimal medical therapy and objective evidence of left ventricular systolic dysfunction
(echocardiographic LVEF < 45%). Exclusion criteria were acute coronary syndrome
within the preceding three months, primary valvular heart disease and stroke with
residual neurological deficit. The study conformed to the principles outlined in the
Declaration ofHelsinki, the protocol had the approval of the local ethics committee and
all patients provided written informed consent.
3.3.2 Sleep study recordings
The study consisted of two comparisons: 1) synchronous in-laboratory study (PSG
versus limited study) and 2) home study (limited study at home versus in-laboratory
PSG on two separate nights). Limited studies were performed using a commercially
available system (Embletta; Flaga, Iceland). Synchronous in-laboratory Embletta (LE)
and PSG, and home Emblettta (HE), studies were performed on two separate nights
(time interval between studies: median 2, range 1-7 days). The Embletta device
measured the following: 1) nasal pressure using a nasal cannula/pressure transducer
system (recording the square root of pressure as an index of flow), 2) thoraco-abdominal
movement from two piezoelectric belts, 3) finger pulse oximetry and 4) body position
(Figure 4.1). Patients were educated in the application of the Embletta device prior to
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the home study and applied the device themselves at home. They were provided with
written instructions and a night-time telephone number to call in the event of
difficulties. Patients required sufficient agility to apply the thoraco-abdominal bands,
nasal cannula and pulse oximeter and connect a single connector to the recording
device. No calibration was required when the Embletta was applied.
Polysomnography was performed following our standard laboratory protocol with a
computerised recording system (Compumedics, Abbotsford, Australia) consisting of: 1)
sleep monitoring through electro-encephalogram, electro-oculogram, and submental
plus outer canthi electromyogram, 2) bilateral tibial electromyogram and body position
detector, 3) nasal pressure using a nasal cannula/pressure transducer system, 4) thoraco¬
abdominal movement from two inductance plethysmographic belts, 5) finger pulse
oximetry, 6) snoring detection by digital microphone and 7) three-lead
electrocardiogram^ 172)
3.3.3 Analysis of sleep study recordings
All sleep studies were scored according to standard criteria by the same experienced
sleep technician who was blinded to the patients' identities.(177) Analysis of recordings
was batched to ensure that no comparisons could be made between individual studies.
Apnoeas were defined as a complete cessation in airflow lasting >10s, and hypopnoeas
as a reduction in airflow or thoraco-abdominal movement by >50% for >10s. Apnoeas
were classified as 1) obstructive if thoraco-abdominal movement was present during the
apnoea; 2) central if thoraco-abdominal movement was absent; and 3) mixed if thoraco-
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abdominal movements were both present and absent during the period of airflow
cessation.(30)
The in-laboratory PSG yielded two apnoea/hypopnoea measures: 1) an
apnoea/hypopnoea index (AHI) which was calculated by dividing the total number of
apnoeas and hypopnoeas after sleep onset by the total sleep time, and 2) an
apnoea/hypopnoea measure per hour in bed (A+H) calculated by dividing the total
number of apnoeas and hypopnoeas by the number of hours in bed. As the Embletta
device does not record sleep, only an apnoea/hypopnoea measure per hour in bed (A+H)
was calculated: A+Hle for the synchronous laboratory Embletta and A+Hhe for the
home Embletta study. The start and end of the laboratory Embletta analysis were set
according to the start and end time of the synchronous PSG thus allowing a direct
comparison in techniques. For the home Embletta, analysis was started once respiration
settled to a stable rhythmic pattern and stopped either according to the time of
awakening as provided by the patient or based on tracing quality and breathing pattern.
Patients were divided into 3 groups on the basis of the Embletta results: no SDB,
possible SDB and definite SDB (A+H<10, A+H 10-20, A+H>20 per hour in bed
respectively) according to our laboratory protocol for the investigation ofOSAHS.(l 14)
This enabled us to assess agreement outcome between the Embletta and laboratory PSG.
Patients were diagnosed as having SDB if they had an AHI of >15 on PSG. Patients
were then classified as OSA if the apnoeas detected were predominantly obstructive,
and CSA if predominantly central. Hypopnoeas were not further classified as this is not
possible without invasive measures.
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3.3.4 Statistical analysis
The Bland and Altman method was used to assess agreement between two methods of
clinical measurement i.e. portable limited study and laboratory PSG, taking into
consideration differences in scoring criteria.(194) Correlation between two measures
was assessed by Pearson's method. Diagnostic accuracy ofpatients' classification into 3
groups (no SDB, possible SDB, definite SDB) based on the limited study was assessed
by kappa statistics which evaluated outcome agreement between Embletta and
laboratory PSG studies. Two-tailed, paired t-tests were used to detect any significant
differences between sleep study measurements. Data are presented as mean ± standard
deviation unless stated otherwise and p<0.05 was accepted as statistically significant.
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Figure 3.1
Limited sleep study demonstrating obstructive sleep apnoea/hypopnoea
Continued thoraco-abdominal movement during apnoeas and hypopnoea is associated
with oxygen desaturations and snoring and indicates obstructive aetiology (intermittent
complete or partial upper airway occlusion). Note the limited sleep study does not
record an electroencephalogram and therefore actual sleep time cannot be accurately
assessed.
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Patients (Table 3.1) were typically late middle-aged or elderly with mild to moderate
symptomatic CHF (NYHA class 2 or 3) due to LV systolic dysfunction and were on
appropriate medical therapy. They were not markedly overweight (BMI 29±6 kg/m2)
and did not report excessive daytime sleepiness (Epworth score 8±4). The study group
had a mean sleep efficiency (% time in bed for sleep actually spent asleep) of 57±21%
and mean total sleep time of 4.0±1.6 hours. Mean AHI was 26±22 and mean central
apnoea index 3±10 per hour of sleep. Eleven (55%) patients had an AHI >15 per hour.
One patient had CSA and the other 10 patients OSA; only 2 of these patients reported




A single nasal cannula was used per study and divided to provide an input to both PSG
and the Embletta. This minimised patient discomfort whilst maintaining adequate nasal




Two of the twenty home Embletta studies had intermittently poor nasal pressure traces;
however these studies, whilst suboptimal, were interpretable with the combined use of
nasal pressure and thoraco-abdominal movement traces. An additional two home
studies had no oxygen saturation tracing and one further study was repeated due to
patient error.
3.4.3 Diagnostic accuracy
3.4.3.1 Synchronous in-laboratory study - PSG v Embletta (LE)
Mean A+H per hour in bed measured by PSG was 24±17 compared to 20+16 by
synchronous LE (Table 3.2; p<0.01). There was a close correlation between the results
of the two studies (r=0.92, p<0.01) and Bland Altman analysis (PSG-LE) showed a
mean bias of 5±7/hr and limits of agreement of -8 to +18/hr (Figure 3.2a). Comparison
of LE A+H per hour in bed to PSG AHI per hour slept also showed good correlation
and agreement (r=0.94, p<0.01; mean bias 6±9, limits of agreement -11 to +24) (Figure
3.2b). There was good agreement in outcomes between LE and PSG A+H in the in-
laboratory synchronous study (kappa coefficient 0.63, p<0.01). Sensitivity and
specificity values for LE were 91% and 89% (AHI > 15) and 83% and 50% (AHI > 5)
respectively. Positive and negative predictive values were 91% and 89% (AHI >15)
and 94% and 100% (AHI > 5) respectively.
53
3.4.3.2 Home study - PSG v Embletta (HE)
Mean A+H per hour in bed measured by HE was 14±13 compared to 24±17 by PSG on
separate nights (Table 3.2; p<0.01). There was reasonable correlation between measures
(r=0.54, p=0.01) with mean bias (PSG-HE) of 10±15/hr and limits of agreement of-18
to +39/hr (Figure 3.2c). Further comparison of the HE A+H per hour in bed to the PSG
AHI per hour slept revealed a mean bias of 12±19 and limits of agreement of -25 to +49
(Figure 3.2d). Differences between measures were more likely to occur at higher event
rates and therefore, when measures > 40 per hour were excluded, there appeared to be
greater agreement (A+H (PSG-HE): 9+8, PSG AHI - HE A+H: 7±8).
Ten of the twenty patients had a HE A+H per hour in bed <10, of whom 5 had PSG
AHI < 15 and 5 had AHI > 15 per hour slept. Six patients had a HE A+H per hour in
bed in the range of 10-20, and of these 2 had AHI < 15 and 4 had AHI > 15 on PSG. Of
the 4 patients with HE A+H of> 20 per hour in bed, all but one had AHI > 15 on PSG;
in this one patient most events occurred during awake time which could not be
determined from the Embletta study. However, agreement in outcomes between HE and
PSG AHI was poor (kappa coefficient 0.27, p=0.06). Sensitivity and specificity values
for HE were 45% and 89% (AHI >15) and 83% and 50% (AHI > 5) respectively.
Positive and negative predictive values were 83% and 57% (AHI >15) and 99% and
25% (AHI > 5) respectively.
The percentage of the night spent supine was higher on the in-laboratory compared to
the home night as determined by the Embletta device [median (IQR) LE 49 (25,99)%,
HE 26 (11,42)%], as was the mean A+H per hour in bed (LE 20+16, HE 14+13). Supine
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A+H was 24±21 and 22±19 per hour in bed (p=0.81), and non-supine A+H 12±14 and
22±18 per hour in bed (p=0.12), for the home and in-laboratory Embletta studies
respectively. Although not used in the definition of respiratory events, 4% desaturation
frequencies varied between devices and were lower (p=0.04) with PSG than with





Patient characteristic Mean ± SD
Age (years) 61±10
Sex (male:female) 14:6
Body mass index (kg/m2) 29±6
Aetiology ofCHF
Ischaemic heart disease 13 (65%)
Dilated cardiomyopathy 7 (35%)
Atrial fibrillation 3 (15%)
Left ventricular ejection fraction (%) 33±12
Drug treatment
ACE inhibitors / ARBs 18 (90%)





Epworth sleepiness score 8±4
PSG measurements
AHI 26±22
Total sleep time (hours) 4.0±1.6
Sleep efficiency (%) 57±21
Oxygen saturation (%) 93±3





Sleep study measurement Embletta Embletta PSG*
Mean ± SD
Obstructive apnoeas 22.6±36.3 33.9±64.5 26.7±62.5
Obstructive apnoeas per hour 2.9±5.1 4.5±8.1 6.3±13.4
Central apnoeas 1.8±5.0 4.4±14.4 11.2±35.4
Central apnoeas per hour 0.2±0.6 0.6±1.8 2.8±9.6
Mixed apnoeas 0.0±0.0 0.3±0.9 0.1±0.2
Mixed apnoeas per hour 0.0±0.0 0.0±0.1 0.0±0.0
Hypopnoeas 87.7±78.0 104.2±10.0 60.9±47.8
Hypopnoeas per hour 10.6±8.9 14.4±10.0 16.4±13.5
Total apnoeas + hypopnoeas 112.1±103.4 142.7±122.3 98.8±93.1
Apnoea + hypopnoeas per hour
in bed (A+H) 13.7±12.6 19.5±16.0 24.2±16.8
Apnoea hypopnoea index
(AHI) - - 25.7±22.2
Total time in bed (Embletta) /
asleep (PSG) (hours) 8.2±1.4 7.3±0.8 4.0±1.6
Sleep efficiency (%) - - 57±21
Oxygen saturation (%) 94±2 93±3 93±3
Oxygen desaturations >4% per
hour 7.5±7.1 14.9±15.4 4.8±6.9
*Events recorded during sleep unless otherwise stated.
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Figures 3.2a-d
Scatter plots (left) with lines of equality. Bland Altman plots (right) where the middle
dotted line represents the mean bias and the outer dotted lines represent the 95% limits
of agreement. PSG: polysomnography, LE: in-laboratory Embletta, HE: home
Embletta, A+H: apnoeas + hypopnoeas per hour in bed, AHI: apnoea/hypopnoea index
per hour slept.
Figure 3.2a
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This is the first study to evaluate the use of a portable limited sleep study system,
performing both synchronous in-laboratory (PSG v limited) and home studies, in the
diagnosis of SDB specifically in patients with CHF. Agreements in diagnostic outcome
between home Embletta and PSG, and negative predictive value for the home Embletta,
were poor. We explore possible explanations for this, both technical and situational,
which need to be taken into consideration, particularly when investigating patients with
CHF.
There is currently no accepted, widely available screening tool for SDB in CHF
patients. This is despite an increasing body of evidence demonstrating the importance of
the co-existence of SDB and CHF, and the potential treatment benefits of non-invasive
ventilation. PSG is relatively expensive, not widely available and demand already
exceeds supply, at a time when only a minority of patients with CHF are investigated
and treated for SDB. Furthermore, there is considerable overlap between symptoms of
CHF and SDB. It is therefore difficult to see how the yield on PSG can be increased if
we are unable to predict clinically which patients are likely to have SDB. In addition,
there may be significant cardiovascular benefits to be gained by treatment, even in the
absence of symptoms of SDB.
Portable limited sleep study systems have been shown to be both useful and cost-
effective in the diagnosis of OSAHS,(l 14-117; 119; 196) and may therefore be of value
in the diagnosis of SDB in CHF patients.(197) In this study, the Embletta performed
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well compared to PSG when examined under identical patient and environmental
conditions. However, it compared less well when tested in the home setting, for which it
was specifically designed and in which it is almost exclusively used in clinical practice.
It provided some useful information, in that a positive result was very likely to reflect a
positive PSG result; however a negative result did not exclude the diagnosis ofSDB and
therefore further investigation by PSG would be required. Overall, agreement in
diagnostic outcome between home Embletta and PSG, and the negative predictive value
of the Embletta, were poor.
Possible explanations for this poor agreement can be due to both technical i.e. Embletta
vs PSG and situational i.e. home vs in-laboratory differences. It is important to
recognize the differences between the measures obtained by the Embletta and PSG. The
Embletta device does not record sleep, and sleep onset and awakening times are inferred
from a combination of breathing pattern, movement and information provided by the
patient. As a result, events occurring whilst the patient is awake may be included in the
A+H per hour in bed. This therefore differs fundamentally from the AHI calculated
from PSG. The favourable results of the synchronous study do not indicate a sensor
problem with the Embletta as the cause, although it is interesting to note the difference
in oximetry results between the two systems.
Significant night-to-night variation in respiratory events has been demonstrated in
OSAHS and, indeed, is more marked in those with mild OSAHS.(198) Patients may
sleep better in the home environment compared to the unfamiliar surroundings of the
sleep laboratory. Body position, with more time spent supine in-laboratory than at
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home, is another extremely important factor which may contribute to the observed
differences.(199) Indeed we have also shown that time spent supine and A+H were
greater in-laboratory compared to at home. It may be therefore that the home, rather
than in-laboratory, study is a more accurate reflection of the 'true' burden of SDB.
These technical and situational factors may be further influenced by the differing
characteristics of the patient population being studied. Differences between
apnoea/hypopnoea measures observed in the current study were approximately twice
those of comparable studies in patients with suspected OSAHS from the general
population.(22;l 15;116) These studies all showed a tendency for the portable study to
underestimate the PSG AHI. One possible reason to account for this greater difference
is the reduced total sleep time and poorer sleep efficiency amongst patients with
CHF.(22;23) Mean sleep efficiency recorded in this study was 57±21 %, compared to
76±2 % in a similar study conducted by our group in sleepy patients with suspected
OSAHS.(114) As a result, sleep, and its associated respiratory events, occurs for a
smaller proportion of the night leading to greater underestimation of event rate by the
Embletta. Many factors may contribute to poor sleep efficiency in CHF patients. These
include both symptoms of CHF, such as orthopnoea, paroxysmal nocturnal dyspnoea
and nocturia, and other factors, such as more advanced age and associated co-morbidity,
unwanted effects of medication and psychosocial effects of chronic illness. These
symptoms of CHF may also fluctuate further contributing to variation in respiratory
event rates. Also, CHF patients are generally less active than OSAHS patients, and
subjectively less sleepy.
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Our results contrast with previous work comparing a different home limited sleep study
(Apnoescreen II; Erich Jaeger Gmbh & CoKg, Wuerzburg, Germany), which used
thermistors to detect airflow, with PSG on separate nights for the diagnosis of SDB in
CHF.(197) This group reported high sensitivity and specificity, indeed achieving higher
values than in studies for the diagnosis of OSA in patients without CHF, which is
perhaps surprising when the factors discussed above are taken into consideration. Others
have reported promising results with overnight home oximetry as a tool for identifying
SBD in patients with CHF, but this technique is limited by the inability to distinguish
between obstructive and central events.(200;201)
The study patient group was recruited from our local CHF out-patient cardiology clinic
population. The total percentage of patients found to have SDB (58%), based on PSG
AHI >15, was comparable with previous studies of CHF and SDB.(23;49) However, in
contrast to earlier studies which have reported a prevalence of CSA in CHF patients of
up to 45%,(23;49;52) we found predominant CSA in only one of our twenty patients
and a very low central apnoea index across the group as a whole. This may be explained
by our modest sample size but may also be due to differences in scoring techniques and
classification criteria between sleep laboratories, in addition to advances in
pharmacological therapy.
3.5.1 Study Limitations
Limitations of this study include the site of the studies and the sample size. We
performed the synchronous study in the sleep laboratory setting since this is the location
where most diagnostic studies are performed and because in-laboratory PSG is the
63
nearest to a gold standard that exists. We did not perform synchronous PSG during the
home studies as it was our aim to evaluate the Embletta as it would be used in the
clinical setting. However, we cannot therefore prove whether sleep quality was also
poorer in the home setting for these CHF patients. Furthermore, we did not assess night-
to-night variability in this study, which may have contributed to our findings. We
believe that the sample size was adequate to demonstrate good agreement between the
Embletta and PSG in the synchronous study and also to provide important insight into
the potential use and limitations of the Embletta device as a diagnostic tool in the home
environment. However, we accept that the modest sample size may have contributed to
our findings of poor agreement between home Embletta and PSG. Based on our
previous work in patients with OSAHS, the study had 80% power to detect a difference
of 8 in A+H between home Embletta and PSG.(114)
Another theoretical limitation might be differences in technology used by the two
devices. The Embletta, for example, used a different oximeter to the PSG. However, as
we used the American Academy of Sleep Medicine definition of significant respiratory
events, which does not require desaturation, this would not affect the results.(202) Some
of the published studies did require desaturation for a significant event to occur and thus
their identification of events would both be oximeter dependent and vary with the extent
of hypoxaemia of the patient, and thus reflect severity of CHF, age and lung disease.
Also of note, the Embletta studies did not include ECG monitoring and therefore do not
provide information regarding heart rate, rhythm and ECG morphology, changes in
which may be frequent in this population.
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Both systems recorded flow by nasal pressure as well as thoracoabdominal movement
and used these signals to define hypopnoeas. Hypopnoeas cannot be differentiated with
certainty between central or obstructive from surface techniques and therefore we report
events/hr rather than central events and obstructive events separately.
3.5.2 Conclusions
Agreement in diagnostic outcome between home limited sleep studies and in-laboratory
PSG, and the negative predictive value of the home limited sleep study, were poor.
These findings may be explained by both technical and situational factors which may be
more marked in this patient population with poor sleep efficiency, and should be taken
into consideration when considering potential screening or diagnostic tools for sleep-
disordered breathing in patients with CHF.
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CHAPTER 4
SLEEP DISORDERED BREATHING IN PATIENTSWITH
CHRONIC HEART FAILURE
Contemporaryprevalence and characteristics
Smith LA, Vennelle M, Denvir MA, Douglas NJ, Newby DE. Contemporary prevalence




The aim of this study was to evaluate prospectively the prevalence and type of SDB in
patients with CHF receiving contemporary modern therapy. Eighty-five patients with
stable symptomatic CHF underwent screening for SDB by home sleep study. Daytime
sleepiness was assessed by the Epworth Sleepiness Scale and CHF severity by symptom
class, LVEF and serum NT-proBNP. Patients (61 ±9 years, LVEF 28±9%) were treated
with ACE inhibition or angiotensin receptor blockade (95%), beta-blockade (76%),
spironolactone (38%), diuretics (82%) and digoxin (32%). SDB [>15
apnoeas/hypopnoeas (A+H) per hour] was present in 23 (27%) patients (A+H 25±9/h,
oxygen desaturations 20±13/h). Of these, 22 patients (26%, 95% confidence interval 17-
36%) had obstructive sleep apnoea (OSA) and only one had central sleep apnoea (1%,
95% confidence interval 0-7%). There were no differences in symptom class, LVEF,
NT-proBNP or Epworth Sleepiness Score between those with and without SDB. There
was no correlation between A+H and LVEF (rs=-0.02, p=0.87) or NT-proBNP (rs=0.23,
p=0.06). SDB is common in patients with stable CHF but is difficult to diagnose
because of the major overlap in symptomatology. In the era of modern therapy, SDB is
predominantly OSA with no clear relationship with severity of CHF.
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4.2 INTRODUCTION
SDB is characterised by recurrent apnoeas and hypopnoeas with disruption of normal
ventilation and sleep architecture. The prevalence of SDB in the healthy middle-aged
population is estimated to be 4-9%.(34) In contrast, early studies have reported that
SDB is very common in ambulatory patients with CHF: up to 62% depending on
diagnostic threshold and selection criteria chosen.(23;49;52) However, these data
predate recent important advances in drug and device therapy, which have improved
morbidity and mortality,(15-17) and are now widely adopted in guidelines for the
optimal management ofpatients with CHF.(1;7)
SDB in patients with CHF often passes unrecognized and yet is associated with
increased morbidity and mortality and presents a potential therapeutic target.(51;107)
SDB is associated with systemic hypertension,(76;80) increased inflammatory mediator
concentrations,(81) increased sympathetic nervous system activation,(93) vascular
endothelial dysfunction(78) and adverse cardiac performance:(79) all mechanisms by
which SDB may contribute to the progression of CHF. Most studies have reported a
predominance of CSA rather than OSA.(23;49;52) However, CSA is associated with
markers of increased severity of CHF(55-58) and its presence may be simply an
indicator of decompensated heart failure and elevated left ventricular filling pressures.
Indeed, patients receiving interventions of proven benefit in CHF, namely beta-blocker
and cardiac resynchronization therapy, have a lower prevalence and severity of
CSA.(110; 111)
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The aims of the study were to determine prospectively the prevalence of SDB in
patients with stable symptomatic CHF on optimal medical therapy according to
contemporary guidelines and also to investigate the clinical characteristics of patients
with SDB compared to those without SDB. We hypothesised that the prevalence of





Patients were recruited from general cardiology clinics at two university hospitals in
Edinburgh and from a specialist heart failure clinic in Glasgow. Consecutive patients
aged between 18 and 80 years with symptomatic (NYHA class II-IV) but stable CHF
for at least one month on maximally tolerated medical therapy and objective evidence of
left ventricular systolic dysfunction (echocardiographic LVEF < 45%) were enrolled
into this prospective study. Exclusion criteria were acute coronary syndrome within the
preceding three months, implantation of a pacemaker or defibrillator within the
preceding six months, primary valvular heart disease, sustained ventricular arrhythmias
(but not atrial fibrillation) and stroke with residual neurological deficit. The study
conformed to the principles outlined in the Declaration ofHelsinki, the protocol had the




Study participants underwent detailed clinical assessment, symptomatic evaluation
(NYHA class and ESS), transthoracic echocardiography, blood sample collection and
home limited sleep study. Investigations were performed within a 4 week period with
clinical stability in all patients.
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4.3.2.2 Sleep study recordings
Limited sleep studies were performed using a commercially available system (Embletta;
Flaga, Iceland) measuring: 1) nasal pressure using a nasal cannula/pressure transducer
system (recording the square root ofpressure as an index of flow), 2) thoraco-abdominal
movement from two piezoelectric belts, 3) finger pulse oximetry and 4) body position.
Patients were educated in the application of the Embletta device prior to the study and
applied the device themselves at home. They were provided with written instructions
and a night-time telephone number to call in the event of difficulties. Patients required
sufficient agility to apply the thoraco-abdominal bands, nasal cannula and pulse
oximeter and connect a single connector to the recording device. No calibration was
required.
4.3.2.3 Sleep study analysis
All sleep studies were scored according to standard criteria by the same experienced
sleep technician (M.V.) who was blinded to the patients' identities.(177) Apnoeas were
defined as a complete cessation in airflow lasting >10 s, and hypopnoeas as a reduction
in airflow or thoraco-abdominal movement by >50% for >10 s. Apnoeas were classified
as 1) obstructive if thoraco-abdominal movement was present during the apnoea; 2)
central if thoraco-abdominal movement was absent; and 3) mixed if thoraco-abdominal
movements were both present and absent during the period of airflow cessation.(30)
Analysis was started once respiration settled to a stable rhythmic pattern and stopped
either according to the time of awakening as provided by the patient or based on tracing
quality and breathing pattern.
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4.3.2.4 Echocardiography
Trans-thoracic Doppler echocardiography was performed by a single, experienced and
blinded research sonographer using an ATL HDI 5000 system (Philips Medical Systems
Limited, Stevenage, U.K). Left ventricular volumes and ejection fraction were
calculated according to modified Simpson's rule.
4.3.2.5 Neurohumoral markers
Blood samples were collected in EDTA with additive trasylol and spun at 1000 g for 20
minutes at 4°C. The plasma was then extracted and frozen in aliquots at -40 °C until
analysis. N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations were
measured using a chemiluminescent immunoassay (Roche Diagnostics Ltd, Lewes,
U.K.) on an Elecsys 2010 analyser.
4.3.3 Statistical analysis
Statistical analyses were performed using Statistical Package for Social Sciences
version 10 software (SPSS inc., Chicago, U.S.A). Continuous variables are expressed
as mean values (±SD), or when not normally distributed data as medians (interquartile
range). Differences between groups were assessed by two-tailed, unpaired t-tests. NT-




Eighty-five patients with stable symptomatic CHF were screened for SDB by home
limited sleep study (Table 4.1). Patients were predominantly male (87%) with a mean
age of 61±9 years, overweight [BMI 30±5 kg/m2] and had moderately severe CHF
(LVEF 28±9%) of predominantly ischaemic aetiology. They were predominantly
NYHA class 2 and only 18 (21%) reported excessive daytime sleepiness (ESS>10).
Patients were on appropriate contemporary medical therapy for CHF due to left
ventricular systolic impairment, including ACE inhibition or angiotensin II receptor
blockade in 95%, beta-blockade in 76% and spironolactone in 38%.
4.4.2 Prevalence and type of sleep-disordered breathing
Significant SDB [> 15 apnoeas/hypopnoeas (A+H) per hour in bed] was present in 23
(27%) patients (A+H 25±9 /h) and they had an increased frequency in oxygen
desaturation (20+13 /h v 7+5 /h, p<0.001) (Table 4.2). Of these, 22 (26% total) had
predominant OSA and only 1(1% total) predominant CSA. Using a lower threshold of
A+H >10 /h, the prevalence of SDB increased to 42%, but only 1 further patient was
identified with predominant CSA. Seven (8%) patients had A+H > 30 respiratory events
per hour.
4.4.3 Characteristics of patients with sleep-disordered breathing
Patients with SDB were more likely to have hypertension (57% v 27%, p=0.02) but
there were no differences in age, sex, body mass index, aetiology of CHF or the
73
presence of diabetes or atrial fibrillation between the two groups (Table 4.1). The
prevalence of SDB did not differ when patients were stratified according to BMI (BMI
> 30 kg/m2, 28%; BMI < 30 kg/m2, 30%, p=0.81). Patients with and without SDB did
not differ in terms of severity of CHF (NYHA class, LVEF, NT-proBNP) or in
subjective assessment of symptoms (NYHA class, ESS) (Table 4.2). Furthermore, there
was no correlation between A+H and LVEF (rs=-0.02, p=0.87) and only an apparent
trend towards a correlation between A+H and NT-proBNP (rs=0.23, p=0.06) (Figures
4.1 and 4.2). ESS did not correlate with A+H (rs=0.05, p=0.64). The only univariate
predictor of SDB identified in this group of patients with CHF was hypertension [odds
ratio 3.44 (1.27-9.31), p=0.02].
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Table 4.1
All No SDB SDB P value
(n=85) (n=62) (n=23)
Age (years) 61±9 60±10 63±8 0.11
Sex (maleifemale) 74:11 52:10 22:1 0.27
Body mass index (kg/m2) 30±5 30±5 30±5 0.51
CHF aetiology (ischaemicrnon) 54:31 37:25 17:6 0.31
Hypertension 30 (35%) 17(27%) 13 (57%) 0.02
Diabetes mellitus 15 (18%) 9(15%) 6 (26%) 0.22
Atrial fibrillation 21 (25%) 14 (23%) 7 (30%) 0.57
Drug treatment
ACEI / ARB 81 (96%) 60 (97%) 21 (91%) 0.29
Beta blockade 67 (79%) 52 (84%) 15 (65%) 0.17
Digoxin 30 (37%) 20 (32%) 10 (43%) 0.44
Diuretics 70 (83%) 51 (82%) 19 (83%) 1.00
Spironolactone 32 (38%) 23 (37%) 9 (39%) 1.00
NYHA class 2.2±0.5 2.2±0.4 2.3±0.6 0.22
Never smoked 26 (31%) 18 (29%) 8 (35%) 0.79
ACEI: angiotensin converting enzyme inhibition, ARB: angiotensin receptor blockade,
NYHA: New York Heart Association.
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Table 4.2
No SDB (n=62) SDB (n=23) P value
Sleep Data (per hour)
A+H 7±4 25+9 <0.001
Obstructive apnoeas 1±1 6+5 <0.001
Central apnoeas 0±1 3+5 <0.001
Mixed apnoeas 0±0 0+1 0.048
Hypopnoeas 6±3 16+6 <0.001
O2 desaturations >4% 7±5 20+13 <0.001
Echocardiography
LA diameter (mm) 44±7 47+9 0.26
LVEDD (mm) 60+12 65+10 0.06
LVESD (mm) 50+11 52+9 0.40
Fractional shortening (%) 19+7 18+6 0.60
LVEF (%) 29+9 27+7 0.41
Neurohumoral markers
NT-proBNP (pg/mL) 810(1623) 1693 (2430) 0.18
Symptoms
NYHA class 2.2+0.4 2.3+0.6 0.22
ESS 7+4 7+4 0.84
A+H: apnoeas + hypopnoeas, LVEDD: left ventricular end-diastolic dimension,
LVESD: left ventricular end-systolic dimension, LVEF: left ventricular ejection
fraction, NT-proBNP: N-terminal pro-brain natriuretic peptide, NYHA: New York
Heart Association, ESS: Epworth Sleepiness Score
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Figure 4.1
Relationship between A+H and NT-proBNP
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4.5 DISCUSSION
SDB remains common in patients with symptomatic stable CHF but is difficult to
diagnose because of the major overlap in symptomatology. However, in the era of
modern CHF therapies, SDB is predominantly OSA and CSA is now relatively unusual.
Furthermore, there is no clear relationship with the severity of CHF, and characteristics
such as increased BMI and subjective daytime sleepiness are much less helpful in this
patient population than in OSAHS.
4.5.1 Changing prevalence & type of sleep-disordered breathing
Our data show the prevalence of significant SDB, defined by A+H >15 events per hour,
was 27% in this cohort of patients with stable symptomatic CHF, with a predominance
ofOSA (26%) compared to CSA (1%). This lower prevalence of SDB is approximately
half the reported rate and is attributable to a marked reduction in CSA, with earlier
studies reporting a prevalence of CSA varying between 29 and 62% in patients with
CHF.(23;49;51;52;107;203) In comparison to these previous studies, our patients were
similar in terms of age, sex and NYHA class although LVEF (28% v 21-23%) and BMI
(30 kg/m2 v 26-28 kg/m2) were slightly higher. It should be noted that the patients
studied retrospectively by Sin et al were a selected group in that they had been referred
to a sleep laboratory with clinical suspicion of SDB.(23) There were differences in the
type of sleep studies, scoring criteria and diagnostic thresholds employed. However,
even adopting the lower threshold for SDB used by Lanfranchi et al, prevalence in this
study is still only 42% compared to 74%.(51) We suggest that this lower prevalence of
SDB, with the observed reduction in CSA, is due to improvements in the modern
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treatment ofpatients with CHF. Previous studies largely predate the routine use ofbeta-
blockade, spironolactone and angiotensin II receptor blockade in this patient population
and the percentage of patients receiving ACE inhibition was
lower. (23 ;49 ;51 ;52; 107 ;203)
More recent data are conflicting with an overall prevalence of SDB of between 24 and
71% with no consensus on the predominant type of SDB.(55-60) In keeping with our
findings, others have reported a reduction in CSA.(55;60;109) There is undoubtedly
some variation in patient characteristics between studies, and indeed CSA is known to
be associated with severely reduced LVEF and higher NYHA class. However, patients
were generally maintained on current optimal medical therapy, and the discrepancy in
findings from studies examining the prevalence and type of SDB in the stable out¬
patient CHF population may largely be explained by the differing types of sleep study,
scoring criteria and diagnostic thresholds. This lack of standardisation makes
comparison difficult.
Classification of respiratory events into obstructive or central may be challenging and
both often coexist in the same patient. Currently there is clinical uncertainty and no
uniform consensus regarding the definition of a hypopnoea.(l 12) Groups differ in
whether oxygen desaturation (of varying magnitude) and/or arousal are required for a
hypopnoea to be identified and this is further influenced by the type of equipment
utilised to detect changes in breathing. Identification of events is therefore both
oximeter dependent and varies with the extent of hypoxaemia, thus reflecting severity of
CHF, age and lung disease. A number of differing technologies to determine respiratory
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effort are available increasing variability in results. Pneumotachography and body
plethysmography have traditionally been considered the gold standards for assessment
of tidal volume and or flow rate, and thus detection of apnoeas and hypopnoeas.
Pharyngeal and oesophageal manometry can be used to determine estimates of airflow
and respiratory effort. However, none of these techniques is suitable for routine PSG.
Thermal and nasal pressure sensors, and inductance plethysmography, are therefore
widely used in sleep laboratories as physiological sensors, but have some limitations.
Thermal sensors, in particular, do not provide quantitative measures of airflow for
detection of hypopnoeas.(204;205) Nasal pressure transducers, adapted to detect flow
limitation, improve hypopnoea detection and have been validated against
pneumotachography, as has calibrated inductance plethysmography, although the
systems used are generally uncalibrated.(204;206;207) Pulse transit time may be used as
a surrogate marker of oesophageal pressure to aid detection and classification of
events.(208;209) Supplementary information gained from the sleep study, such as
interrogation of the snoring channel, may also aid the scorer. However, it is clear that
differences in both techniques and technologies utilised to perform the sleep study, and
in its scoring and interpretation, will affect intra and interlaboratory variability and
published data.
The distinction between OSA and CSA is clinically relevant because it influences
treatment strategy. Randomised controlled trials in patients with OSA and CHF have
shown that CPAP improves quality of life, reduces blood pressure and sympathetic
nervous system activity, and may improve cardiac function.(142;144;210) The
management of CSA however, other than by optimisation of CHF therapy, is more
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controversial. CPAP and adaptive servo-ventilation improve daytime sleepiness, cardiac
function and sympathetic activity but the recently reported CANPAP trial did not
demonstrate a beneficial effect ofCPAP on morbidity or mortality in patients with CHF
and CSA. (106; 109;147; 158; 163)
4.5.2 Characteristics of patients with chronic heart failure and sleep-disordered
breathing
It would be extremely useful to be able to predict which patients with CHF have a
higher likelihood of SDB and would therefore benefit from sleep assessment and, in the
setting of symptomatic OSA, CPAP or non-invasive ventilation. This is particularly
important given the often slow access to sleep studies.(l 13)
Whilst we have shown that SDB (essentially OSA) remained relatively common in this
population, its presence did not impact on symptoms, functional status or measures of
severity of CHF. Patients with SDB were more likely to have hypertension than those
without SDB, an interesting observation in this cohort of patients with CHF due to
impaired LV systolic function. In patients with normal LV systolic function, the results
of large epidemiological studies support a causative role for OSA in the development of
systemic hypertension, independent of other potential confounding
variables.(33;80;211-213) Furthermore, treatment of OSA with CPAP has been shown
to lower both daytime and nocturnal blood pressure.(76;124;125) Control of blood
pressure is extremely important in patients with CHF, and the development or
exacerbation of systemic hypertension associated with OSA presents one potential
mechanism by which the progression ofCHF may be accelerated.
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There were no differences in age, gender, BMI, aetiology of CHF, drug therapy or the
presence of diabetes or atrial fibrillation between those patients with SDB and those
without SDB. The ESS was not a helpful tool in predicting SDB, as reported
elsewhere.(59;195) This is perhaps unsurprising as there is considerable overlap
between the symptoms of CHF and SDB, and although these patients have objectively
measured daytime sleepiness, few actually complain of it.(22;49; 195) Sin et al found
BMI >35 kg/m2 to be a risk factor for OSA in men with CHF (odds ratio 6.10[2.86-
13.00]) but in our patient cohort, and others, this was not a helpful
discriminator. (23 ;5 5 ;57)
Central sleep apnoea was rare in our study population and therefore our findings do not
enable us to examine the characteristics of patients with heart failure and CSA.
Previously identified risk factors for CSA include age > 60 years, male gender, atrial
fibrillation and hypocapnia; others report an association between CSA and indices of
increased severity of CHF.(23;55-58) However, it is difficult to know whether these
indices are simply a reflection of more severe CHF rather than the presence of CSA.
Furthermore, comparisons in the literature between groups of CHF patients with OSA
and CSA need to be interpreted with care as there are often significant differences in
apnoea/hypopnoea index (AHI) and CHF indices between groups.
4.5.3 Study limitations
We used a limited sleep study to evaluate SDB rather than in-laboratory PSG, which
many regard as the gold standard. Limited studies are a more accessible alternative to
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full PSG and have been well validated against PSG in the investigation of OSAHS in
the general population.(l 13; 114; 119) Patients may not sleep as well in the unfamiliar
surroundings of the sleep laboratory and it may be that a home study is a more accurate
reflection of the true burden of SDB. However, there is a tendency for limited studies,
which record respiratory events per hour in bed rather than per hour of sleep, to
underestimate the PSG AHI.(22;115;116) This may be exaggerated further by the
reduced total sleep time and poorer sleep efficiency observed in patients with
CHF.(22;23) It is possible that, in comparison to studies conducted using PSG, the
prevalence of SDB has been underestimated in our study and, as such, does not reflect
the true prevalence of SDB in the CHF population. However, previous studies using
similar techniques still found a high prevalence of SDB and CSA.(51;57;60) It is also
not possible to assess the presence of periodic limb movements during sleep with our
limited studies and this disorder itselfmay impact on symptoms.
Whilst some groups attempt to classify hypopnoeas, we believe these cannot be
differentiated definitively with surface techniques, and therefore have not attempted to
do so. However, we acknowledge that, particularly where hypopnoeas rather than
apnoeas predominate, this may influence the designated type of SDB. This is one reason
which may help explain the low prevalence of CSA in our study, in addition to the
differences in prevalence ofSDB reported in the literature.
Patients with recent implantation of a cardiac pacemaker or defibrillator were excluded
from this study. As cardiac resynchronization therapy becomes more widespread this
may perhaps further reduce the prevalence of SDB.
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Finally, participants in CHF research studies tend to be younger, well-motivated and
have fewer comorbidities than non-participants and thus our cohort of patients may not
be characteristic of the wider CHF population.(214;215)
4.5.4 Conclusions
Sleep-disordered breathing remains relatively common in patients with stable CHF on
optimal contemporary medical therapy. However, contrary to previous data, this is
predominantly OSA and CSA is now rare. It is difficult to identify SDB clinically in
patients with CHF: ESS score and BMI are less helpful in this patient population.
Clinicians should be alert to the presence of, and the requirement for sleep studies to
diagnose SDB in patients with CHF. Furthermore, there is a need for greater
standardisation in scoring and classification criteria for SDB in CHF to enable
meaningful comparisons and appropriate treatment decisions to be made.
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CHAPTER 5
AUTO TITRATING CONTINUOUS POSITIVE AIRWAY
PRESSURE THERAPY IN PATIENTSWITH CHRONIC HEART
FAILURE AND OBSTRUCTIVE SLEEP APNOEA
A RANDOMISED PLACEBO CONTROLLED TRIAL
Smith LA, Vennelle M, Gardner RS, McDonagh TA, Denvir MA, Douglas NJ, Newby
DE. Auto-titrating continuous positive airway pressure therapy
in patients with chronic heart failure and obstructive sleep apnea:
A randomized placebo controlled trial.
Eur Heart J 2007;28:1221-1227
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5.1 SUMMARY
Obstructive sleep apnoea is highly prevalent in patients with CHF and may contribute to
CHF progression. We aimed to determine whether treatment ofOSA with CPAP would
improve subjective and objective measures of heart failure severity in patients with CHF
and OSA. 26 patients with stable symptomatic CHF and OSA were randomised to
nocturnal auto-titrating CPAP or sham CPAP for 6 weeks each in crossover design.
Study co-primary endpoints were changes in peak VO2 and 6-minute walk distance.
Secondary endpoints were changes in LVEF, VE/VCO2 slope, plasma neurohormonal
markers and quality of life measures. 23 patients completed the study protocol. Mean
CPAP and sham CPAP usage were 3.5±2.5 and 3.3±2.2 h/night respectively (p=0.31).
CPAP treatment was associated with improvements in daytime sleepiness (ESS score
7±4 vs 8±5, p=0.04) but not in other quality of life measures. There were no changes in
other study endpoints. In patients with CHF and OSA, auto-titrating CPAP improves
daytime sleepiness but not other subjective or objective measures of CHF severity.
These data suggest that the potential therapeutic benefits of CPAP in CHF are achieved
by alleviation ofOSA rather than by improvement in cardiac function.
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5.2 INTRODUCTION
Chronic heart failure is a major cause ofmorbidity and mortality in developed countries
and its prevalence and incidence continues to rise.(3) The Sleep Heart Health Study has
shown a cross-sectional association between OSA and CHF.(98) Although often
unrecognised, OSA is highly prevalent in patients with CHF: up to 37%, depending on
diagnostic threshold and selection criteria chosen.(23;49) Furthermore, severe OSA is
an independent risk factor for fatal and non-fatal cardiovascular events, and this risk
may be reduced by the application of nocturnal CPAP.(97)
Obstructive sleep apnoea is characterised by intermittent partial or complete upper
airway obstruction during sleep disrupting normal ventilation and sleep architecture.
OSA is associated with systemic hypertension,(76;80;216) vascular endothelial
dysfunction,(77;78) increased sympathetic nervous activity(82) and increased levels of
inflammatory mediators.(81) In addition, inspiration against the occluded upper airway
generates exaggerated negative intra-thoracic pressure which adversely affects cardiac
performance.(74) These important factors are all implicated in the development and
progression ofCHF.
There have been only two previous randomised controlled trials to assess CPAP in
patients with CHF and OSA.(142;144) These trials report improvements in left
ventricular ejection fraction, overnight urinary norepinephrine excretion, systolic blood
pressure and some quality of life measures. However, they employed parallel group
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comparisons with small numbers of patients (n=12-19 per group) and, importantly, no
appropriate placebo control.
The aim of this study therefore was to determine whether, using a double blind
randomised placebo controlled crossover trial, treatment of OSA by nocturnal auto-




Patients were recruited from general cardiology clinics at two university hospitals in
Edinburgh and from a specialist heart failure clinic in Glasgow. Consecutive patients
with CHF aged between 18 and 80 years were enrolled into this prospective study if the
following inclusion criteria were met: 1) symptomatic CHF (NYHA class II-IV), 2)
LVEF determined by echocardiography of < 45%, 3) clinical stability for at least one
month, 3) optimal medical therapy, and 4) AHI > 15 (predominantly obstructive) on
PSG. Exclusion criteria were acute coronary syndrome within the preceding three
months, primary valvular heart disease, sustained ventricular arrhythmias (but not atrial
fibrillation) and stroke with residual neurological deficit. The study complied with the
Declaration ofHelsinki, the protocol had the approval of the local ethics committee and
all patients provided informed written consent.
5.3.2 Procedures
5.3.2.1 Sleep studies
Patients with 15 or more apnoeas/hypopnoeas per hour in bed on a limited sleep study
performed at home were invited to attend for PSG at the Sleep Centre in Edinburgh.
PSG was performed following our standard laboratory protocol (172) with a
computerised recording system (Compumedics, Abbotsford, Australia) consisting of: 1)
sleep monitoring through electro-encephalogram, electro-oculogram, and submental
plus outer canthi electromyogram, 2) bilateral tibial electromyogram and body position
89
detector, 3) nasal pressure using a nasal cannula/pressure transducer system, 4) thoraco¬
abdominal movement from two inductance plethysmographic belts, 5) finger pulse
oximetry, 6) snoring detection by digital microphone and 7) three-lead
electrocardiogram.
All sleep studies were scored according to standard criteria by the same experienced
sleep technician.(177) Apnoeas were defined as a complete cessation in airflow lasting
>10 s, and hypopnoeas as a reduction in airflow or thoraco-abdominal movement by
>50% for >10 s. Apnoeas were classified as 1) obstructive if thoraco-abdominal
movement was present during the apnoea; 2) central if thoraco-abdominal movement
was absent; and 3) mixed if thoraco-abdominal movements were both present and absent
during the period of airflow cessation. (30)
5.3.2.2 Study protocol
This was a double-blind randomised placebo controlled crossover trial in patients with
CHF and OSA. Patients were randomised to nocturnal auto-titrating CPAP (Autoset
Spirit: ResMed, Sydney, Australia) and sham CPAP for 6 weeks each in a cross-over
design with a 1 week washout period. Randomisation to treatment order was performed
following baseline assessment using sealed envelopes and a balanced block design with
6 patients per block. Study co-primary endpoints were changes in peak VO2 and 6-
minute walk distance. Secondary endpoints were changes in LVEF, VE/VCO2 slope,
plasma neurohormonal markers and quality of life measures.
Auto-titrating CPAP automatically adjusts pressure according to upper airway
obstruction, avoiding many of the disadvantages of titration and treatment with
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conventional CPAP. It is as effective as fixed pressure CPAP in reducing daytime
sleepiness and AHI, and also increases nightly use, provides better quality sleep and less
discomfort.(133; 134) Sham CPAP was chosen as the placebo in the present study
because it was felt important to control for the discomfort and possible sleep disruption
of wearing a mask overnight; it also makes observer blinding easier to maintain. The
sham device was created by setting delivered airway pressure to a minimum, insertion
of a flow restricting connector at the machine outlet and creation of an extra hole in the
collar of the main tubing at the end of the mask.(180) . The device delivered a CPAP
pressure of approximately 1 cm ITO.
Patients underwent an initial daytime education session and were then supervised for
their first night on each device in the Sleep Centre. They were asked to use the machine
for a minimum of six hours per night at home and provided with a contact telephone
number in case of any problems. In addition, all patients were contacted by telephone
by the Sleep Centre Research Nurse within 2 weeks of taking each device home.
Compliance with therapy was assessed by interrogation of the CPAP unit to provide
nightly usage data.
Study investigators performing assessments were blinded to treatment modality; they
were not involved in randomisation, device education or follow-up and study
participants were instructed not to discuss their device with them. Study participants
themselves were advised that two different types of breathing device were being tested
and that they would receive both in a random order.
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Functional evaluation was performed at the coordinating centre at baseline, 6 and 13
weeks and included: 1) clinical assessment, 2) trans-thoracic echocardiography, 3)
symptom-limited cardiopulmonary exercise testing, 4) 6 minute walk test, 5)
neurohumoral markers, 6) OSLER test (175) and 7) quality-of-life assessment. At
baseline evaluation, two 6 minute walk and two cardiopulmonary exercise tests were
performed on separate days to minimise any potential bias due to a training effect; the
second tests were taken as baseline data.
5.3.2.3 Cardiopulmonary exercise testing
Symptom-limited exercise tests were performed under physician supervision using an
electronically-braked cycle ergometer. The incremental exercise protocol was
individualised aiming for exercise duration between 8 and 12 minutes.(190) A 12-lead
electrocardiogram was monitored continuously during the test and cuff blood pressure
was recorded manually every two minutes. Patients were asked to exercise to
exhaustion and all tests were conducted under physician supervision. Respiratory gas
exchange measurements were obtained breath-by-breath using a computerised
metabolic cart (MSX, Ferraris Group Pic, Birmingham, U.K). Gas and flow
calibrations were performed before each test.
Breath-by-breath data were formatted using a rolling eight breath average. Peak VO2,
VCO2 and VE were recorded as the highest such values within the last 30 seconds of the
test. Predicted peak VO2 values were calculated using the standard formulae described
by Wasserman et al.( 191) The anaerobic threshold was determined non-invasively using
a dual method (V-slope and ventilatory equivalents) approach as the respiratory
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exchange ratio approximated unity.(192) The VE/VCCb slope was calculated as a linear
regression function, excluding the non-linear part of the relationship after the onset of
acidotic drive to ventilation.(190)
5.3.2.4 Six minute walk test
A standardised test procedure was followed.(189) Patients were asked to walk around a
walking track, covering as much distance as possible during 6 minutes, and were
allowed to rest if required.
5.3.2.5 Echocardiography
Trans-thoracic Doppler echocardiography was performed by a single, experienced
research sonographer using an ATL HDI 5000 system (Philips Medical Systems
Limited, Stevenage, U.K). Left ventricular volumes and ejection fraction were
calculated according to modified Simpson's rule.
5.3.2.6 Clinical and Quality-of-Life Assessment
Clinical assessment was performed at each study visit and NYHA class recorded.
Standardised questionnaires (SF-36, Minnesota Living with Heart Failure and Epworth
Sleepiness Scale (188)) were used to assess quality of life and symptoms.
5.3.2.7 Neurohumoral markers
Blood samples were collected in EDTA with additive trasylol or 2% sodium
metbisulphite and spun at 1000 g for 20 minutes at 4°C. The plasma was then extracted
and frozen in aliquots at -40 °C until analysis. NT-proBNP and NT-proANP were
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measured using a chemiluminescent immunoassay (Roche Diagnostics Ltd, Lewes,
U.K.) on an Elecsys 2010 analyser. Plasma norepinephrine concentrations were
determined by an electrochemical method after separation by reverse phase high
performance liquid chromatography.(193)
5.3.3 Statistical analysis
Statistical analyses were performed using Statistical Package for Social Sciences
version 10 software (SPSS inc., Chicago, U.S.A). Continuous variables are expressed
as mean values (±SD), or when not normally distributed data as medians (interquartile
range). Differences between the changes in outcome measures with intervention, i.e.
CPAP and sham CPAP, were compared by two-tailed, paired t-tests. NT-proBNP and
NT-proANP data were normalised by logarithmic transformation prior to assessment.
The study had 80% power, at 5% significance level, to detect absolute differences in the
primary end-points of 1.1 mL/min/kg in peak VO2 and 33 m in 6-minute walk distance,
assuming standard deviation of expected changes of 1.9 mL/min/kg and 57 m
respectively. Statistical significance was taken at the 5% level.
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5.4 RESULTS
Of the 349 patients who potentially fulfilled the entry criteria, 114 consented to undergo
study screening (Figure 5.1). Sleep studies were performed on 103, with 46
subsequently attending for in-laboratory PSG. Of the 29 patients fulfilling all trial entry
criteria, 2 withdrew consent for personal reasons and 1 died prior to randomisation
(ruptured abdominal aortic aneurysm). Twenty-six patients were randomised and, of
these, two withdrew immediately following the baseline assessment for personal
reasons, and one withdrew after completion of the first limb of the study because of
mask claustrophobia. One patient was excluded from the final analysis because multiple
changes to drug therapy, instituted by the patient's attending physician, were deemed
likely to influence trial endpoints. No time-order effects were observed.
5.4.1 Patient characteristics and continuous positive airway pressure use
Study patients were predominantly late middle-aged men (Table 5.1) maintained on
optimal drug therapy for LV systolic dysfunction. The study population demonstrated
moderately severe obstructive sleep apnoea, although only 8 patients (31%) complained
of excessive daytime sleepiness (Table 5.2). Mean nightly CPAP and sham CPAP use
were similar: 3.5±2.5 and 3.3±2.2 hours per night respectively (p=0.31). Mean CPAP
pressure applied was 7±2 cm H2O.
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5.4.2 Outcome data
There were subjective but no objective improvements in daytime sleepiness with auto-
titrating CPAP therapy (Table 5.3). No differences were demonstrated in other quality
of life measures such as the SF-36 and Minnesota Living with Heart Failure
questionnaire scores (Table 5.3, Figure 5.2). Similarly, there were no differences in
cardiac function, exercise capacity or neurohormonal activation between CPAP and






Body mass index (kg/m2) 31±4
Hypertension 11 (42%)




Ischaemic heart disease 12
Dilated cardiomyopathy 12
Other 2
Atrial fibrillation 8 (31%)
Drug treatment
ACE /ARB 25 (96%)




NYHA class - II / III / IV 20/5/1
Mean±SD or number (%).
ACE, angiotensin converting enzyme inhibitor; ARB,





Epworth Sleepiness Score 10±5
OSLER time (mins) 29±15
Obstructive apnoeas (per hour) 11±15
Central apnoeas# (per hour) 1(4)
Mixed apnoeas# (per hour) 0(1)
Hypopnoeas (per hour) 22±17
Apnoea/hypopnoea index (AHI) 36±23
Total sleep time (hours) 4.6±1.5
Sleep efficiency (%) 61±17
Oxygen saturation (%) 93±2
Oxygen desaturations >4% (per hour) 22±26




Effect ofCPAP and sham CPAP on quality of life and cardiac function
Treatment
Baseline Sham CPAP effect P value
Echocardiography
LVESD (mm) 50±11 51±13 51±14 -0.1 (-0.4-0.3) 0.79
LVEDD (mm) 61±10 63±12 63±12 0.0 (-0.4-0.3) 0.83
FS (%) 18±7 20±8 19±6 0.1 (-3.3-3.6) 0.95
LVEF (%) 29±10 30±10 30±10 0.7 (-1.8-3.2) 0.56
Exercise capacity
6 MW (m) 550±121 552±121 546±124 0 (-14-14) 0.98
Exercise time 10.0±2.3 9.7±3.0 9.8±3.1 0.2 (-0.3-0.7) 0.44
(mins)
Peak VO2 14.8±4.2 14.7±4.6 14.5±4.2 -0.2 (-0.9-0.4) 0.48
(mL/kg/min)
VE/VCCb slope 32±5 33±7 33±8 -0.3 (-1.9-1.4) 0.73
Quality of life
Minnesota 38±27 34±28 36±29 1.0 (-4.3-6.4) 0.70
SF-36 - physical 34±16 35±14 34±14 -1.0 (-3.6-1.6) 0.43
SF-36 - mental 51±10 50±11 49±12 -0.5 (-4.2-3.2) 0.79
Daytime sleepiness
ESS 10±5 8±5 7±4 -1 (-1.9-0.0) 0.04
OSLER (mins) 27±15 29±13 30±14 0.7 (-2.2-3.6) 0.63
Mean±SD except treatment effect (95% confidence interval). ESS, Epworth Sleepiness
Scale; FS, fractional shortening; LVEDD, left ventricular end-diastolic dimension;
LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection
fraction; OSLER, Oxford SLEep Resistance test; 6 MW, 6 minute walk test.
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Figure 5.1
CONSORT diagram of trial recruitment.
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Figure 5.2
Effect ofCPAP and sham CPAP on quality of life measures (SF-36).
PF, physical function; R-P, role - physical; R-E, role - emotional; SF, social function;
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5.5 DISCUSSION
We have conducted the first randomised double blind placebo controlled cross-over
trial of auto-titrating nocturnal CPAP therapy in patients with CHF and OSA. In
contrast to smaller previous trials, CPAP improves daytime sleepiness but not other
subjective or objective measures of CHF severity. These data suggest that the
potential therapeutic benefits of CPAP in CHF are achieved by alleviation of OSA
rather than by improvement in cardiac function. However, the efficacy of CPAP as a
treatment for patients with CHF and OSA may be limited in part by poor patient
tolerability and compliance.
Important advances have been made in the management of patients with CHF in the
last two decades. A range of therapeutic options that are known to impact on
symptoms, quality of life and prognosis are now available to the physician. However,
the prevalence of CHF continues to rise, associated morbidity and mortality rates
remain high, and the financial burden to healthcare systems is great.(3) The
identification of potential exacerbating factors and possible therapeutic targets
therefore remains extremely important. OSA is one such factor that commonly co¬
exists with CHF, may contribute to disease progression and can be potentially
targeted by CPAP therapy.
Two recently published randomised controlled trials in patients with CHF and OSA
are encouraging.(93;142) These trials reported that CPAP therapy improved LVEF,
systolic blood pressure and symptoms. However, these studies had important
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limitations including the single-blind design and the small numbers of patients
(n=12-19 per intervention group) completing study protocols. Some of the study
findings were not entirely consistent given that there were no changes in peak VO2 or
NYHA class despite improvements in LVEF.
Previous trials of CPAP have used non-intervention control groups raising concerns
regarding potential placebo effects and adequate blinding. This is a particular
problem when using device interventions that require training, supervision and close
liaison with healthcare professionals. Prior work with CPAP in patients with OSAHS
has revealed a powerful placebo effect, reducing ESS score by 2 points and
improving other quality of life measures.(127;140) Failure to control for a placebo
effect could therefore overestimate differences in endpoints between intervention and
non-intervention groups. We therefore used sham CPAP as a placebo control and, in
our study, there were no differences in compliance or drop-out rates between sham
and active CPAP limbs suggesting that patient blinding was maintained and that an
effective placebo was indeed employed.
Results of parallel group studies involving small numbers of patients are susceptible
to bias introduced by baseline differences between control and treatment groups as
well as by outliers. For example, the control group in the Kaneko et al trial had
significantly worse OSA than the treatment group at baseline and this may have led
to worsening of cardiovascular variables over the conduct of the trial.( 142)
Decisions whether to include or exclude outliers in statistical analysis, or inadequate
matching of outcome variables at study entry, such as LVEF and AHI thresholds,
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may markedly alter statistical results and reported outcomes. Indeed, the impact of
outliers and the methods of statistical analysis on the results of the study by
Mansfield et al have been discussed elsewhere.(217)
Determining the effects of CPAP on cardiovascular outcomes in patients with CHF
and OSA remains an extremely important clinical question. The present study
utilized a robust randomised double-blind placebo controlled crossover trial design
that enables patients to act as their own control, thus reducing between-subject
variability, avoiding the need for matched control subjects, and increasing statistical
power. Indeed, our analysis of 23 patients yields a power 2-4 times greater than that
of the previously published parallel group studies.(20;21) The entry criteria and
endpoints for the current study were well-defined and clinically relevant. Robust
symptomatic and quality of life assessments are vital when considering CPAP as a
potential treatment as the patient's perception of benefit is a major determinant of
future compliance with therapy. Peak Vo2, Ve/VC02 slope and NT-proBNP all
provide important prognostic information in CHF.(184-186) LVEF also provides
useful information but correlates poorly with symptoms and functional limitation in
CHF.(187) Major treatment advances in the management of CHF patients, such as
the introduction of ACE inhibitors, beta-blockers and, more recently, biventricular
pacing have been shown to improve these parameters and subsequently, in large
randomised controlled trials, to reduce hospitalisation rates and
mortality. (9; 13; 15; 16)
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We have shown small and clinically modest improvements in subjective, but not
objective, measures of daytime sleepiness with CPAP that are not due to a placebo
effect. This is perhaps not surprising as the aetiology of sleepiness in patients with
CHF is clearly multifactorial. In contrast to previous work, no improvements in
quality of life measures, functional capacity or other markers of CHF severity were
identified with CPAP therapy in this patient group. This is despite the greater
severity of both CHF and OSA in our study population compared to that of
Mansfield et al. (144)
Compliance with CPAP therapy in this study was reasonable, particularly when the
reduced total sleep time is considered, but was poorer than that achieved in other
studies.(142;144) This was despite careful education, initiation of treatment in-
laboratory and the provision of ongoing support, suggesting that CPAP may not be
acceptable to a proportion of patients with CHF and OSA. Previous work in patients
with OSAHS has shown that there is a need to derive symptomatic benefit from
CPAP in order to accept the associated discomfort and inconvenience. Accordingly,
compliance and long-term usage in patients with mild OSAHS is poor.(140)
Similarly, patients with CHF and OSA who do not have excessive daytime
sleepiness, or whose sleepiness is due to factors other than OSA, may not comply
with CPAP therapy. We did not find the ESS and OSLER tests to be helpful in




The study protocol did not include follow-up PSG. Our aim was to investigate
whether auto-titrating CPAP was a tolerable and effective treatment for patients with
CHF and OSA rather than whether auto-titrating CPAP reduced AHI. Whilst not
routinely performed in the clinical setting, we accept that a follow-up PSG would
have been helpful to ensure efficacy of the treatment intervention.
Inadequate reduction in AHI, due to limited subject compliance, would be a possible
explanation for the lack of efficacy of CPAP therapy for cardiovascular endpoints.
However, it is important to note the low total sleep times observed in this study: in
itself an interesting and important finding in patients with CHF. Moreover, CPAP
use was greater than that observed in our previous studies of patients with OSAHS
where we have shown that CPAP therapy produced significant improvements in both
quality of life and cardiovascular endpoints.(76;140) Furthermore, Bradley et al
demonstrated sustained improvements in LVEF and plasma norepinephrine
concentrations with comparable nightly CPAP use (3.6 hours at 12 months), albeit in
CHF patients with central sleep apnoea rather than OSA.(109) We also accept that
the duration of treatment in the present study may have been insufficient to
demonstrate effects on cardiovascular endpoints although previous work has shown
benefits after only 4 weeks of treatment.(76;125;142; 143)
We used the American Academy of Sleep Medicine definition of significant
respiratory events which does not require oxygen desaturation when flow is
measured by nasal pressure rather than thermal signal.(30) Our system recorded flow
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by nasal pressure in addition to thoraco-abdominal movement and these signals were
used to identify hypopnoeas. Hypopnoeas cannot be differentiated with certainty
between central or obstructive from surface techniques and therefore we report
events per hour rather than central and obstructive events separately. The study
cohort showed a moderate degree of OSA with the majority of respiratory events
being hypopnoeas, a proportion of which may have been central in nature. Based on
these results, it is not possible to exclude benefit from auto-titrating CPAP in patients
with concomitant severe OSA and CHF.
5.5.2 Conclusions
Auto-titrating nocturnal CPAP improves subjective daytime sleepiness but not other
quality of life measures or markers of CHF severity in patients with CHF and OSA.
These data suggest that symptomatic benefit in this patient group is achieved by
alleviation of OSA rather than by improvement in cardiac function. The efficacy of
CPAP as a treatment for patients with CHF and OSA may in part be limited by poor
patient tolerability and compliance. On the basis of our findings, we believe that this
approach is unlikely to provide a major therapeutic impact on the morbidity and
mortality associated with chronic heart failure.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
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6.1 DETECTION AND DIAGNOSIS OF SLEEP-DISORDERED
BREATHING IN PATIENTS WITH CHRONIC HEART FAILURE
There is currently no accepted, widely available screening tool for SDB in patients
with CHF. PSG is relatively expensive, not widely available and demand currently
exceeds supply, at a time when only a minority of patients with CHF is investigated
and treated for SDB.(113)
Portable limited sleep study systems are both useful and cost-effective in the
diagnosis of OSAHS.(l 14-117; 119;218) For the first time, a limited sleep study
system has been evaluated, performing both synchronous in-laboratory (PSG versus
limited) and home studies, in the diagnosis of SDB specifically in patients with
CHF.(24) The limited sleep study compared well with PSG when tested under
identical patient and environmental conditions but much less so when tested in the
home setting. This finding can be explained by a number of technical and situational
factors which are further exacerbated in patients with CHF. The limited sleep study
system does not record sleep and, as such, tends to underestimate the PSG
AHI.(22;115; 116) Patients with CHF have lower total sleep times and sleep
efficiency and, as a result, there is even greater underestimation of respiratory event
rate.(22-24) The symptoms of CHF, in addition to more advanced age and associated
co-morbidity, side-effects of medication and psychosocial effects of chronic illness
all contribute to poor sleep. These symptoms also fluctuate further contributing to
night-to-night variation in respiratory events.(198) Furthermore, patients may sleep
better in the home environment compared to the sleep laboratory and this may
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influence body position and subsequently respiratory event rate.(199) Therefore, it is
possible that studies conducted in the home environment, rather than in-laboratory,
are a more accurate reflection of the true burden of SDB. These factors should be
taken into consideration when considering potential screening or diagnostic tools for
SDB in patients with CHF.
Health care professionals need to be alert to the presence and clinical relevance of
SDB in patients with CHF. There is a need for greater awareness and education for
both patients and clinicians with respect to both good sleep hygiene and SDB. Based
on current available data, PSG should be considered in those patients with CHF who
complain of excessive daytime sleepiness despite optimal modern CHF therapy.
There is insufficient evidence of treatment benefit presently to support widespread
screening for SDB in patients with CHF. Additional work is required in the
development of screening tools for the identification of SDB in large populations.
Alternative screening tools such as nocturnal pulse oximetry and heart rate variability
are currently subjects of research but have important limitations.(201;219-223) It
appears that the need to determine sleep is of greater importance in patients with
CHF and the development of a limited sleep study system with a modified EEG may
prove helpful in this regard.
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6.2 CONTEMPORARY PREVALENCE OF SLEEP-DISORDERED
BREATHING IN PATIENTS WITH CHRONIC HEART FAILURE
SDB remains relatively common, but with lower prevalence than previously
reported, in patients with symptomatic stable CHF due to left ventricular systolic
dysfunction on optimal contemporary medical therapy.(23;49;52;55-60) However,
contrary to previous data, SDB is predominantly obstructive in aetiology, and CSA
and CSR are now rare in this setting. It is likely that this lower prevalence of SDB,
and the observed reduction in CSA, is due to improvements in the modem treatment
ofpatients with CHF.
Recent data, however, are conflicting with an estimated overall prevalence ofSDB of
between 24 and 71% with no consensus on the predominant type of SDB.(55-60)
This discrepancy in findings in similar patient cohorts maintained on comparable
medical therapy may be explained by lack of standardisation with respect to type of
sleep study, scoring criteria and diagnostic thresholds.
Classification of respiratory events may be challenging, particularly as obstructive,
central and mixed events may all exist in the same patient.(94;95) There is a lack of
consensus regarding the definition and classification of hypopnoeas in particular and
this may influence the designated predominant type of SDB. The distinction between
OSA and CSA is clinically important because it influences treatment strategy.
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There is considerable overlap in the symptoms ofCHF and SDB, and, whilst patients
with CHF have objectively measured daytime sleepiness, few complain of
it.(22;49;195) Indeed, in this study cohort, the presence of SDB did not impact on
symptoms, functional status or measures of severity ofCHF. The ESS and BMI were
not helpful in predicting the presence of SDB. It is difficult therefore to identify SDB
clinically in patients with CHF and clinicians should be alert to the requirement for
sleep studies to diagnose SDB in this patient population.
As therapies for CHF continue to advance, there will be a need to reassess at
intervals the prevalence, pathophysiology and clinical relevance of SDB to guide
research and clinical activity. OSA, rather than CSA and CSR, is currently the
predominant type of SDB in patients with CHF, and with risk factors for OSA and
CHF in the general population increasing, the prevalence is likely to continue to rise.
OSA should therefore now be the focus of attention. Furthermore, there is an urgent
need for greater agreement and standardisation in scoring and classification criteria
for SDB in CHF to enable meaningful comparisons and appropriate treatment
decisions to be made. Without this, it will be difficult to further advance knowledge
in this important area and enable the transition from research into clinical practice.
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6.3 TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN PATIENTS
WITH CHRONIC HEART FAILURE
In the first randomised placebo-controlled crossover trial of auto-titrating nocturnal
CPAP in patients with CHF and OSA, CPAP improves subjective daytime sleepiness
but not other quality-of-life measures or markers of CHF severity.(210) These data
contrast with smaller previous trials and suggest that the potential therapeutic
benefits of CPAP in CHF are achieved by alleviation of OSA rather than by
improvement in cardiac functional42; 144) Compliance with CPAP therapy was
reasonable, considering the reduced total sleep time, but poorer than that achieved in
some other studies.(142;144) This was despite careful education, initiation of
treatment in-laboratory and provision of ongoing support, suggesting that CPAP may
not be acceptable to a proportion of patients with CHF and OSA. Patients need to
perceive symptomatic benefit from CPAP in order to accept the associated
discomfort and inconvenience, which persists despite advances in device technology.
Studies of CPAP in patients with OSA, but no excessive daytime sleepiness, have
failed to show improvements in symptoms or neuro-cognitive function. (224)
Accordingly, patients with OSA and CHF who do not have excessive daytime
sleepiness, or whose sleepiness is due to other factors, may not comply with therapy.
Therefore the efficacy ofCPAP as a treatment for OSA in patients with CHF may be
limited in part by poor patient tolerability and compliance.
It can be seen that OSA is highly prevalent in patients with CHF,(55-60) and via a
variety of haemodynamic, autonomic and vascular effects, may contribute to the
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progression of CHF.(74;76-82;225-228) There are currently no data to suggest that
drug therapies used to treat CHF impact on the severity of OSA.(229) General
measures such as weight loss and avoidance of alcohol and sedatives may be
beneficial however.(43;44;230)The available data regarding the potential benefits of
treating OSA with CPAP in patients with CHF are limited and conflicting.(142-
146;210) Studies have involved small numbers of patients conducted in single
centres with treatment of 1-3 months duration. Based on these data, it is reasonable
to recommend a trial of CPAP therapy for those patients with OSA and CHF with
excessive daytime sleepiness to improve symptoms and quality of life but not to
improve cardiac function, morbidity or mortality. Accordingly, for those patients
with OSA and CHF but without excessive daytime sleepiness, CPAP is not likely to
be either of significant symptomatic benefit or well-tolerated. The occasional finding
of CSA on sleep studies should prompt intensive efforts to optimise and ensure
compliance with CHF therapies. Presently there is no evidence to support the use of
CPAP in these patients as CPAP has not been shown consistently to improve
symptoms or, importantly, morbidity and mortality.(104;109;158)
Currently, there are no large-scale trials investigating the effects ofmedium or long-
term treatment ofOSA on cardiovascular function, morbidity or mortality in patients
with CHF. This work highlights the need for multi-centre randomised controlled
trials with adequate power to address these important questions. Such trials will pose
difficulties in design and execution in view of the large numbers of participants
required, the lack of access to specialist sleep centres and the relatively intensive
nature of the intervention. Concerns have been raised regarding both the ability to
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maintain and the ethics of administering true placebo or sham CPAP over a
prolonged period;(231) however based on the current evidence the number of
patients with CHF and conventional indications for treatment of OSA is small. In
order to facilitate such research greater collaboration will be required between
respiratory and sleep physicians and cardiologists, and also between clinicians and
industry.
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6.4 SYSTEMIC HYPERTENSION IN PATIENTS WITH OBSTRUCTIVE
SLEEP APNOEA AND CHRONIC HEART FAILURE
In patients with normal LV systolic function, the results of large epidemiological
studies support a causative role for OSA in the development of systemic
hypertension, independent of other potential confounding variables.(33;80;211-213)
Furthermore, animal studies, where dogs have been exposed to experimental OSA
for a period of several weeks, have shown that OSA leads to the development of
systemic hypertension, left ventricular hypertrophy and left ventricular systolic
dysfunction.(79;232;233) Hypertension itself is the commonest risk factor for the
development of CHF in longitudinal epidemiological studies.(3;234) The failing left
ventricle is particularly sensitive to small increases in afterload and, accordingly,
control of blood pressure is extremely important in patients with CHF.
Treatment ofOSA with CPAP has been shown to lower both daytime and nocturnal
blood pressure in patients with normal LV systolic function.(76;124;125) Whilst
these reductions in blood pressure have been modest in magnitude, small but
maintained improvements in blood pressure are known to significantly reduce the
incidence of cardiovascular and cerebrovascular disease.(235-238) It is possible
therefore that treatment of OSA with CPAP improves blood pressure control which
may then translate into improvements in overall cardiovascular prognosis.
The development or exacerbation of systemic hypertension associated with OSA
presents one potential mechanism by which the progression of CHF may be
accelerated. In patients with OSA and CHF due to impaired LV systolic function,
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nocturnal blood pressure remains above waking values and elevated daytime blood
pressure has been shown to correlate positively with increasing AHI.(74;239) Small
studies of CPAP in patients with OSA and CHF have shown conflicting effects on
systolic blood pressure.(142; 144)
Currently, it is unknown whether treatment ofOSA with CPAP in patients with CHF
due to LV systolic impairment produces sustained reduction in systemic blood
pressure and whether this in turn might confer any benefit on cardiovascular
morbidity and mortality. Whilst such a study would require very large numbers of
participants to ensure adequate statistical power, this is a potential area of future
research interest.
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6.5 NON-INVASIVE VENTILATION IN PATIENTS WITH CHRONIC
HEART FAILURE: AN UPDATE
At present, sleep apnoea is not a specific therapeutic target in patients with CHF,
despite its high prevalence and impact on morbidity and mortality, and its
management is not addressed in contemporary evidence-based guidelines.(1;7) This
position is appropriate in view of concerns regarding potential early harm with
CPAP, inadequate treatment of central apnoeas with current CPAP devices and a
lack of randomised clinical trial data demonstrating improvement in cardiovascular
outcomes with targeted therapy for SDB in patients with CHF. However, the
possibility of clinical benefit and the lack of other treatments for SDB ensure this is a
vital and active area of ongoing research. More than thirty clinical trials active in the
area of SDB and CHF are registered in ClinicalTrials.gov, the ISRCTN registry and
the WHO International Clinical Trials Registry Platform. These include further trials
investigating the prevalence of SDB in CHF, the utility of various screening tools
and the effects ofCPAP on various measures of cardiovascular function. In addition,
trials of ASV, bi-level non-invasive ventilation, cardiac resynchronisation therapy,
overdrive pacing, nocturnal O2, developmental drugs and exercise in patients with
CHF and SDB are also registered. Other groups are investigating the effects ofCPAP
on cardiac remodeling and metabolism, vascular function and coagulation. However,
none is designed to answer the crucial question of whether specific treatment of SDB
in patients with CHF does indeed reduce cardiovascular event rates.
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6.6 CONCLUSION
SDB is common and clinically relevant in patients with chronic heart failure. The
relationship between SDB and cardiovascular disease is extremely complex and not
yet clearly defined. Better understanding of this relationship, gained from
mechanistic studies, epidemiological research and clinical trials, has the potential to
benefit a large proportion of the population. Closer collaboration is required between
sleep physicians and cardiologists, and between clinicians and industry, both to raise
awareness of the clinical relevance of SDB and to facilitate greater well-designed
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